消化器内科学レビュー　2022-’23

出版社： 総合医学社
著者：
発行日： 2022-07-25
分野： 臨床医学：内科  >  消化器一般
ISBN： 9784883784615
電子書籍版： 2022-07-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,400 円(税込)

購入する

商品紹介

消化器内科学分野のエキスパートによって厳選された、直近2年間を中心に国内外で発表された最新の文献レビューです。
広く消化器内科学関連の最近のトピックスを把握でき、専門医だけでなく、専門医を目指す方にも必携の1冊です。

目次

  • I章　消化管（上・下）
    　1．胃食道逆流症
    　2．食道表在癌に対する診断と治療
    　3．進行食道癌に対する集学的治療
    　4．Helicobacter pylori 関連疾患の現状と今後
    　5．早期胃癌に対する診断と治療
    　6．進行胃癌に対する薬物療法
    　7．十二指腸非乳頭部腫瘍に対する内視鏡診断と治療
    　8．十二指腸乳頭部腫瘍に対する内視鏡的診断と治療
    　9．小腸腫瘍に対する診療の進歩
    　10．潰瘍性大腸炎に対する診療の最前線
    　11．クローン病に対する診療の最前線
    　12．大腸ポリープに対する内視鏡診断と治療法
    　13．早期大腸癌に対する診断と治療
    　14．進行大腸癌に対する治療の最前線
    　15．消化管癌に対する免疫療法のトピックス
    　16．好酸球性消化管疾患に関する話題
    　17．過敏性腸症候群に関するトピックス
    　18．腸内細菌と消化管疾患
    　19．消化管出血の現状と今後の展開
    　20．ベーチェット病と非特異性多発性小腸潰瘍症
    　21．慢性便秘症に関する話題
    　22．AIを用いた内視鏡診療
    　23．高齢者に対する癌治療
    　24．消化管神経内分泌腫瘍に対する集学的治療

    II章　肝
    　25．B型肝炎の創薬
    　26．B型肝炎ウイルス感染と肝免疫
    　27．C型肝炎ウイルス治療の現状と課題
    　28．C型非代償性肝硬変の抗ウイルス治療
    　29．アルコール関連肝疾患の最近の知見
    　30．NAFLDの最近の動向
    　31．期待されるNAFLD/NASH治療
    　32．門脈圧亢進症に対する集学的治療
    　33．非侵襲的肝線維化評価法
    　34．非代償性肝硬変に対する薬物治療（再生・抗ウイルス治療を除く）
    　35．肝硬変に対する再生医療
    　36．肝細胞癌に対する薬物療法
    　37．肝癌診療におけるバイオマーカー
    　38．がんゲノム医療時代の肝細胞癌
    　39．免疫関連有害事象における肝障害
    　40．自己免疫性肝疾患のup to date
    　41．ACLF基準の今後の課題
    　42．うっ血肝のマネジメント
    　43．腸内細菌と肝疾患
    　44．肝疾患とサルコペニア

    III章　胆・膵
    　45．急性膵炎
    　46．慢性膵炎
    　47．自己免疫性膵炎
    　48．胆膵領域における超音波内視鏡診断の進歩
    　49．胆道ドレナージの最前線
    　50．消化管再建症例における胆管結石治療
    　51．IPMNの発癌機序の解明
    　52．膵癌早期診断のための取り組み
    　53．膵胆道癌の早期診断バイオマーカー
    　54．膵胆道癌における個別化医療の現状
    　55．膵神経内分泌腫瘍に対する集学的治療
    　56．がんゲノム医療時代のEUS-TA
    　57．超音波内視鏡下瘻孔形成術の現状と課題
    　58．胆膵癌の緩和ケア

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 消化管 ( 上・下 )

P.3 掲載の参考文献
1) Gyawali CP, Tutuian R, Zerbib F et al:Value of pH impedance monitoring whileon twice-daily proton pump inhibitor therapy to identify need for escalation of reflux management. Gastroenterology 161:1412-1422, 2021
 
2) Zhang M, Yaman B, Roman S et al:Post-reflux swallow-induced peristaltic wave(PSPW):physiology, triggering factors and role in reflux clearance in healthy sub-jects. J Gastroenterol 55:1109-1118, 2020
 
3) Ribolsi M, Frazzoni M, De Bortoli N et al:Reflux characteristics triggering post-reflux swallow-induced peristaltic wave(PSPW)in patients with GERD symptoms. Neurogastroenterol Motil:e14183, 2021[online ahead of print]
 
4) Frazzoni L, Frazzoni M, De Bortoli N et al:Application of Lyon Consensus cri-teria for GORD diagnosis:evaluation of conventional and new impedance-pH para-meters. Gut, 2021[online ahead of print]
 
5) Ribolsi M, Luca Guarino MP, Balestrieri P et al:The results from up-front esopha-geal testing predict proton pump inhibitor response in patients with chronic cough. Am J Gastroenterol 116:2199-2206, 2021
 
6) Sugimoto M, Murata M, Mizuno H et al:Endoscopic reflux esophagitis and reflux-related symptoms after Helicobacter pylori eradication therapy:Meta-analysis. J Clin Med 9:3007, 2020
 
7) Lee KJ, Son BK, Kim GH et al:Ran-domised phase 3 trial:tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oe-sophagitis. Aliment Pharmacol Ther 49:864-872, 2019
 
8) Akiyama J, Hosaka H, Kuribayashi S et al:Efficacy of vonoprazan, a novel potas-sium-competitive acid blocker, in patients with proton pump inhibitor-refractory acid reflux. Digestion 101:174-183, 2020
 
9) Hamada S, Ihara E, Ikeda H et al:Clinical characterization of vonoprazan-refractory gastroesophageal reflux disease. Digestion 102:197-204, 2021
PubMed
10) Vaezi MF, Fass R, Vakil N et al:IW-3718 reduces heartburn severity in patients with refractory gastroesophageal reflux disease in a randomized trial. Gastroenterology 158:2093-2103, 2020
 
11) Spechler SJ, Hunter JG, Jones KM et al:Randomized trial of medical versus surgi-cal treatment for refractory heartburn. N Engl J Med 381:1513-1523, 2019
 
12) Pauwels A, Boecxstaens V, Andrews CN et al:How to select patients for antireflux surgery? The ICARUS guidelines(interna-tional consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for an-tireflux surgery). Gut 68:1928-1941, 2019
 
13) Bell R, Lipham J, Louie BE et al:Magnetic sphincter augmentation superior to pro-ton pump inhibitors for regurgitation in a 1-year randomized trial. Clin Gastroenterol Hepatol 18:1736-1743. e2, 2020
 
14) Ferrari D, Siboni S, Riva CG et al:Mag-netic sphincter augmentation outcomes in severe gastroesophageal reflux disease. Front Med(Lausanne) 8:645592, 2021
 
15) Eusebi LH, Cirota GG, Zagari RM et al:Global prevalence of Barrett's oesopha-gus and oesophageal cancer in individu-als with gastro-oesophageal reflux:a systematic review and meta-analysis. Gut 70:456-463, 2021
 
16) Peters Y, van Grinsven E, Siersema PD:Systematic review with meta-analysis:the effects of family history on the risk of Barrett's oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther 54:868-879, 2021
PubMed
17) Peters Y, Huibertse LJ, Schrauwen RWM et al:Increased risk of Barrett's oesopha-gus and related neoplasia in individuals with a positive family history. Eur J Can-cer 155:116-126, 2021
 
18) Sawas T, Dilmaghani S, Dhaliwal L et al:Risk factor profiles can distinguish esophageal adenocarcinoma from Barrett's esophagus. Am J Gastroenterol 116:198-201, 2021
PubMed
19) Fukuda S, Watanabe K, Yoshida T et al:Low risk of esophageal adenocarcinoma among patients with ultrashort-segment Barrett's esophagus in Japan. Dig Endosc, 2021[online ahead of print]
 
20) Norita K, Koike T, Saito M et al:Long-term endoscopic surveillance for Barrett's esophagus in Japan:Multicenter prospec-tive cohort study. Dig Endosc 33:1085-1092, 2021
 
21) de Mello Del Grande L, Herbella FAM, Katayama RC et al:Transdiaphragmatic pressure gradient(TPG)has a central role in the pathophysiology of gastro-esophageal reflux disease(GERD)in the obese and it correlates with abdominal cir-cumference but not with body mass index(BMI). Obes Surg 30:1424-1428, 2020
 
22) Qumseya BJ, Bukannan A, Gendy S et al:Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc 90:707-717. e1, 2019
 
23) Qumseya B, Gendy S, Wallace A et al:Prevalence of Barrett's esophagus in obese patients undergoing pre-bariatric surgery evaluation:a systematic review and meta-analysis. Endoscopy 52:537-547, 2020
PubMed
24) Usui G, Shinozaki T, Jinno T et al:Asso-ciation between visceral abdominal obesity and long-segment Barrett's esophagus in a Japanese population. J Gastroenterol 55:189-197, 2020
 
25) Schlottmann F, Dreifuss NH, Patti MG:Obesity and esophageal cancer:GERD, Barrett's esophagus, and molecular carci-nogenic pathways. Expert Rev Gastroen-terol Hepatol 14:425-433, 2020
 
26) Maret-Ouda J, Santoni G, Wahlin K et al:Esophageal adenocarcinoma after antire-flux surgery in a cohort study from the 5 Nordic countries. Ann Surg 274:e535-e540, 2021
 
27) Aiolfi A, Micheletto G, Marin J et al:Laparoscopic sleeve-fundoplication for morbidly obese patients with gastro-esophageal reflux:systematic review and meta-analysis. Obes Surg 31:1714-1721, 2021
PubMed
28) Elkassem S:Gastroesophageal reflux dis-ease, esophagitis, and Barrett's esophagus 3 to 4 years post sleeve gastrectomy. Obes Surg 31:5148-5155, 2021
 
29) Qumseya BJ, Qumsiyeh Y, Ponniah SA et al:Barrett's esophagus after sleeve gas-trectomy:a systematic review and meta-analysis. Gastrointest Endosc 93:343-352. e2, 2021
 
30) Fass OZ, Mashimo H:The effect of bariat-ric surgery and endoscopic procedures on gastroesophageal reflux disease. J Neuro-gastroenterol Motil 27:35-45, 2021
 
P.8 掲載の参考文献
1) Yuan XL, Guo LJ, Liu W et al:Artifi-cial intelligence for detecting superficial esophageal squamous cell carcinoma un-der multiple endoscopic imaging modali-ties:A multicenter study. J Gastroenterol Hepatol 37:169-178, 2022
 
2) Waki K, Ishihara R, Kato Y et al:Useful-ness of an artificial intelligence system for the detection of esophageal squamous cell carcinoma evaluated with videos simulat-ing overlooking situation. Dig Endosc 33:1101-1109, 2021
 
3) Fukuda H, Ishihara R, Kato Y et al:Comparison of performances of artificial intelligence versus expert endoscopists for real-time assisted diagnosis of esophageal squamous cell carcinoma(with video). Gastrointest Endosc 92:848-855, 2020
PubMed
4) Ohmori M, Ishihara R, Aoyama K et al:Endoscopic detection and differentiation of esophageal lesions using a deep neural network. Gastrointest Endosc 91:301-309. e1, 2020
 
5) Morita S, Goda K, Yano T et al:Multi-center prospective in vivo study of an en-docytoscope system(ECS)for superficial esophageal cancer. J Gastroenterol 56:808-813, 2021
 
6) Kato M, Hayashi Y, Uema R et al:Ad-ditional effect of magnifying narrow-band imaging on estimating the invasion depth of superficial esophageal cancer. JGH Open 4:178-184, 2019
 
7) Kimura H, Yoshida M, Tanaka M et al:Preoperative indicators of misdiagnosis in invasion depth staging of esophageal can-cer:Pitfalls of magnifying endoscopy with narrow-band imaging. Dig Endosc 32:56-64, 2020
 
8) Gotoda T, Hori K, Nakagawa M et al:A prospective multicenter study of the magnifying endoscopic evaluation of theinvasion depth of superficial esophageal cancers. Surg Endosc, 2021[online ahead of print]
 
9) Tanaka I, Hirasawa D, Saito H et al:The sub-classification of type B2 vessels ac-cording to the magnifying endoscopic clas-sification of the Japan Esophageal Society. Dig Endosc 32:49-55, 2020
 
10) Uema R, Hayashi Y, Tashiro T et al:Use of a convolutional neural network for classi-fying microvessels of superficial esophageal squamous cell carcinomas. J Gastroenterol Hepatol 36:2239-2246, 2021
 
11) Shimamoto Y, Ishihara R, Kato Y et al:Real-time assessment of video images for esophageal squamous cell carcinoma inva-sion depth using artificial intelligence. J Gastroenterol 55:1037-1045, 2020
 
12) Ishihara R, Mizusawa J, Kushima R et al:Assessment of the diagnostic performance of endoscopic ultrasonography after con-ventional endoscopy for the evaluation of esophageal squamous cell carcinoma invasion depth. JAMA Netw Open 4:e2125317, 2021
 
13) Onozato Y, Sasaki Y, Abe Y et al:Novel genomic alteration in superficial esopha-geal squamous cell neoplasms in non-smoker non-drinker females. Sci Rep 11:20150, 2021
 
14) Kim GH, Min YW, Lee H et al:Risk factors of metachronous recurrence after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. PLoS One 15:e0238113, 2020
PubMed
15) Oda I, Shimizu Y, Yoshio T et al:Long-term outcome of endoscopic resection for intramucosal esophageal squamous cell cancer:a secondary analysis of the Japan Esophageal Cohort study. Endoscopy 52:967-975, 2020
PubMed
16) Sakaguchi Y, Tsuji Y, Shinozaki T et al:Steroid injection and polyglycolic acid shielding to prevent stricture after esoph-ageal endoscopic submucosal dissection:a retrospective comparative analysis(with video). Gastrointest Endosc 92:1176-1186. e1, 2020
 
17) Xiang J, Linghu E, Li L et al:Utility of radial incision and cutting with steroid injection for refractory stricture after en-doscopic submucosal dissection for largesuperficial esophageal squamous cell carci-noma. Surg Endosc 35:6930-6937, 2021
 
18) Hazama H, Tanaka M, Kakushima N et al:Predictors of technical difficulty dur-ing endoscopic submucosal dissection of superficial esophageal cancer. Surg En-dosc 33:2909-2915, 2019
 
19) Park YJ, Kim GH, Park DY et al:His-topathologic discrepancies between en-doscopic forceps biopsy and endoscopic resection specimens in superficial esopha-geal squamous neoplasms. J Gastroenterol Hepatol 34:1058-1065, 2019
 
20) Tanaka T, Ueno M, Iizuka T et al:Com-parison of long-term outcomes between esophagectomy and chemoradiotherapyafter endoscopic resection of submucosal esophageal squamous cell carcinoma. Dis Esophagus 32:doz023, 2019
 
21) Minashi K, Nihei K, Mizusawa J et al:Ef-ficacy of endoscopic resection and selective chemoradiotherapy for stage I esophagealsquamous cell carcinoma. Gastroenterol-ogy 157:382-390. e3, 2019
 
22) Kadota T, Minashi K, Wakabayashi M et al:Diagnostic yield of conventional endos-copy with endoscopic ultrasonography for submucosal invasion of superficial esopha-geal squamous cell carcinoma:a post hoc analysis of multicenter prospective con-firmatory study(JCOG0508). Esophagus 18:604-611, 2021
 
23) Aoyama J, Kawakubo H, Mayanagi S et al:Discrepancy between the clinical and final pathological findings of lymph node metastasis in superficial esophageal can-cer. Ann Surg Oncol 26:2874-2881, 2019
 
24) Yachida T, Oda I, Abe S et al:Risk of lymph node metastasis in patients with the superficial spreading type of esopha-geal squamous cell carcinoma. Digestion 101:239-244, 2020
 
25) Kim GH, Min YW, Lee H et al:Risk fac-tors of metachronous recurrence after en-doscopic submucosal dissection for super-ficial esophageal squamous cell carcinoma. PLoS One 15:e0238113, 2020
 
26) Kato K, Ito Y, Nozaki I et al:Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology 161:1878-1886. e2, 2021
 
27) Nozaki I, Machida R, Kato K et al:Long-term survival of patients with T1bN0M0 esophageal cancer after thora-coscopic esophagectomy using data from JCOG0502:a prospective multicenter trial. Surg Endosc, 2021[online ahead of print]
 
28) Nakajo K, Abe S, Oda I et al:Impact of the Charlson Comorbidity Index on the treatment strategy and survival in elderly patients after non-curative endoscopic submucosal dissection for esophageal squamous cell carcinoma:a multicenter retrospective study. J Gastroenterol 54:871-880, 2019
PubMed
29) Maekawa A, Ishihara R, Iwatsubo T et al:High incidence of head and neck cancers after endoscopic resection for esophageal cancer in younger patients. J Gastroenterol 55:401-407, 2020
PubMed
P.15 掲載の参考文献
1) Kelly RJ, Ajani JA, Kuzdzal J et al:Adju-vant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384:1191-1203, 2021
PubMed
2) Wang H, Tang H, Fang Y et al:Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoad-juvant chemotherapy for locally advanced esophageal squamous cell carcinoma:A randomized clinical trial. JAMA Surg 156:444-451, 2021
 
3) Minsky BD, Pajak TF, Ginsberg RJ et al:INT 0123(Radiation Therapy Oncology Group 94-05)phase III trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002
PubMed
4) Hulshof MCCM, Geijsen ED, Rozema T et al:Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer(ARTDECO Study). J Clin Oncol 39:2816-2824, 2021
 
5) Ji Y, Du X, Zhu W et al:Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer:A multicenter randomized phase 3 clinical trial. JAMA Oncol 7:1459-1466, 2021
 
6) Sun JM, Shen L, Shah MA et al:Pem-brolizumab plus chemotherapy versus chemotherapy alone for first-line treat-ment of advanced oesophageal cancer(KEYNOTE-590):a randomised, placebo-controlled, phase 3 study. Lancet 398:759-771, 2021
 
P.19 掲載の参考文献
1) Ford AC, Yuan Y, Moayyedi P:Helico-bacter pylori eradication therapy to prevent gastric cancer:systematic review and meta-analysis. Gut 69:2113-2121, 2020
 
2) Sugimoto M, Murata M, Yamaoka Y:Chemoprevention of gastric cancer devel-opment after Helicobacter pylori eradication therapy in an East Asian population:Meta-analysis. World J Gastroenterol 26:1820-1840, 2020
 
3) Zhao JB, Yuan L, Yu XC et al:Wholefamily-based Helicobacter pylori eradication is a superior strategy to single-infected pa-tient treatment approach:A systematic review and meta-analysis. Helicobacter 26:e12793, 2021
 
4) Zou Y, Qian X, Liu X et al:The effect of antibiotic resistance on Helicobacter pylori eradication efficacy:A systematic review and meta-analysis. Helicobacter 25:e12714, 2020
PubMed
5) Schubert JP, Gehlert J, Rayner CK et al:Antibiotic resistance of Helicobacter pylori in Australia and New Zealand:A system-atic review and meta-analysis. J Gastroen-terol Hepatol 36:1450-1456, 2021
 
6) Sholeh M, Maleki F, Krutova M et al:The increasing antimicrobial resistance of Helicobacter pylori in Iran:A systematic review and meta-analysis. Helicobacter 25:e12730, 2020
PubMed
7) Si XB, Bi DY, Lan Y et al:Gastric juice-based genotypic methods for diagnosis of Helicobacter pylori infection and antibiotic resistance testing:A systematic review and meta-analysis. Turk J Gastroenterol 32:53-65, 2021
PubMed
8) Ye Q, Shao X, Shen R et al:Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy:A systematic review and meta-analysis. Helicobacter 25:e12713, 2020
PubMed
9) Mukai R, Handa O, Suyama Y et al:Ef-fectiveness of including probiotics to Heli-cobacter pylori eradication therapies. J Clin Biochem Nutr 67:102-104, 2020
 
10) Kakiuchi T, Mizoe A, Yamamoto K et al:Effect of probiotics during vonoprazan-containing triple therapy on gut micro-biota in Helicobacter pylori infection:A randomized controlled trial. Helicobacter 25:e12690, 2020
 
11) Yu M, Zhang R, Ni P et al:Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication:A meta-analysis of randomized controlled trials. PLoS One 14:e0223309, 2019
 
12) Schmelz R, Miehlke S, Thiede C et al:Sequential H. pylori eradication and radia-tion therapy with reduced dose compared to standard dose for gastric MALT lym-phoma stagesIE & II1E:a prospective randomized trial. J Gastroenterol 54:388-395, 2019
 
13) Zullo A, Hassan C, Ridola L et al:Eradica-tion therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lym-phoid tissue lymphoma patients:a sys-tematic review. J Clin Gastroenterol 47:824-827, 2013
 
14) Jung K, Kim DH, Seo HI et al:Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lym-phoid tissue lymphoma:A meta-analysis. Helicobacter 26:e12774, 2021
 
15) Takigawa H, Yuge R, Masaki S et al:Involvement of non-Helicobacter pylori he-licobacter infections in Helicobacter pylori-negative gastric MALT lymphoma patho-genesis and efficacy of eradication therapy. Gastric Cancer 24:937-945, 2021
 
16) Mansori K, Moradi Y, Naderpour S et al:Helicobacter pylori infection as a risk fac-tor for diabetes:a meta-analysis of case-control studies. BMC Gastroenterol 20:77, 2020
 
17) Mansori K, Dehghanbanadaki H, Nader-pour S et al:A systematic review and meta-analysis of the prevalence of Heli-cobacter pylori in patients with diabetes. Diabetes Metab Syndr 14:601-607, 2020
 
18) Song X, Cai C, Jin Q et al:The efficacy of Helicobacter pylori eradication in diabet-ics and its effect on glycemic control:A systematic review and meta-analysis. Helicobacter 26:e12781, 2021
 
19) Kim HJ, Kim YJ, Lee HJ et al:System-atic review and meta-analysis:Effect of Helicobacter pylori eradication on chronic spontaneous urticaria. Helicobacter 24:e12661, 2019
 
20) Elhendawy M, Hagras MM, Soliman SS et al:Positive effect of Helicobacter pylori treatment on outcome of patients with chronic spontaneous urticaria. Am J Clin Pathol 155:405-411, 2021
PubMed
21) Doheim MF, Altaweel AA, Elgendy MG et al:Association between Helicobacter pylori infection and stroke:a meta-analysis of 273,135 patients. J Neurol 268:3238-3248, 2021
PubMed
22) Wang B, Yu M, Zhang R et al:A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease. He-licobacter 25:e12761, 2020
 
23) Zhong R, Chen Q, Zhang X et al:Helico-bacter pylori infection is associated with a poor response to levodopa in patients with Parkinson's disease:a systematic review and meta-analysis. J Neurol, 2021[Online ahead of print]
 
24) Bai F, Li X:Association of Helicobacter pylori treatment with Parkinsonism and re-lated disorders:A systematic review and meta-analysis. Life Sci 281:119767, 2021
 
25) Liu Y, Li R, Xue X et al:Periodontal dis-ease and Helicobacter pylori infection in oral cavity:a meta-analysis of 2727 partici-pants mainly based on Asian studies. Clin Oral Investig 24:2175-2188, 2020
 
26) Ozturk A:Periodontal treatment is as-sociated with improvement in gastric Helicobacter pylori eradication:an updated meta-analysis of clinical trials. Int Dent J 71:188-196, 2021
 
27) Bang CS, Lee JJ, Baik GH:Artificial intel-ligence for the prediction of Helicobacter pylori infection in endoscopic images:Systematic review and meta-analysis of diagnostic test accuracy. J Med Internet Res 22:e21983, 2020
 
28) Lui TKL, Tsui VWM, Leung WK:Ac-curacy of artificial intelligence-assisted detection of upper GI lesions:a system-atic review and meta-analysis. Gastrointest Endosc 92:821-830. e9, 2020
 
P.25 掲載の参考文献
1) Kawamura M, Uedo N, Koike T et al:Kyoto classification risk scoring system and endoscopic grading of gastric intes-tinal metaplasia for gastric cancer:mul-ticenter observation study in Japan. Dig Endosc, 2021[online ahead of print]
 
2) Cai Q, Zhu C, Yuan Y et al:Development and validation of a prediction rule for esti-mating gastric cancer risk in the Chinese high-risk population:a nationwide multi-centre study. Gut 68:1576-1587, 2019
 
3) Take S, Mizuno M, Ishiki K et al:Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradica-tion. J Gastroenterol 55:281-288, 2020
 
4) Dohi O, Yagi N, Naito Y et al:Blue laser imaging-bright improves the real-time detection rate of early gastric cancer:a randomized controlled study. Gastrointest Endosc 89:47-57, 2019
PubMed
5) Ono S, Kawada K, Dohi O et al:Linked color imaging focused on neoplasm detec-tion in the upper gastrointestinal tract:A randomized trial. Ann Intern Med 174:18-24, 2021
 
6) Luo H, Xu G, Li C et al:Real-time arti-ficial intelligence for detection of upper gastrointestinal cancer by endoscopy:a multicentre, case-control, diagnostic study. Lancet Oncol 20:1645-1654, 2019
 
7) Wu L, He X, Liu M et al:Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer:a randomized controlled trial. En-doscopy 53:1199-1207, 2021
 
8) Horiuchi Y, Hirasawa T, Ishizuka N et al:Performance of a computer-aided diag-nosis system in diagnosing early gastric cancer using magnifying endoscopy videos with narrow-band imaging(with videos). Gastrointest Endosc 92:856-865. e1, 2020
 
9) Wu L, Wang J, He X et al:Deep learning system compared with expert endosco-pists in predicting early gastric cancer and its invasion depth and differentiation status(with videos). Gastrointest Endosc 95:92-104. e3, 2022
 
10) Takizawa K, Ono H, Hasuike N et al:A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer:Japan Clinical On-cology Group study(JCOG1009/1010). Gastric Cancer 24:479-491, 2021
 
11) 小野裕之, 八尾建史, 藤城光弘 他:胃癌に対するESD/EMRガイドライン(第2版). Gastroenterol Endosc 62:273-290, 2020
 
12) 日本胃癌学会 編:胃癌治療ガイドライン医師用(2021年7月改訂 第6版). 金原出版, 2021
 
13) Tanoue K, Fukunaga S, Nagami Y et al:Long-term outcome of endoscopic submu-cosal dissection for early gastric cancer in patients with severe comorbidities:a comparative propensity score analysis. Gastric Cancer 22:558-566, 2019
 
14) Hatta W, Gotoda T, Kanno T et al:Prevalence and risk factors for lymph node metastasis after noncurative endo-scopic resection for early gastric cancer:a systematic review and meta-analysis. J Gastroenterol 55:742-753, 2020
 
15) Hatta W, Gotoda T, Koike T et al:Is ad-ditional gastrectomy required for elderly patients after endoscopic submucosal dis-section with endoscopic curability C-2 for early gastric cancer? Digestion 103:83-91, 2022
 
P.31 掲載の参考文献
1) Tanaka Y, Chiwaki F, Kojima S et al:Multi-omic profiling of peritoneal metasta-ses in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer 2:962-977, 2021
 
2) Shitara K, Bang YJ, Iwasa S et al:Trastu-zumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382:2419-2430, 2020
 
3) Kang YK, Boku N, Satoh T et al:Nivolumab in patients with advanced gas-tric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2):a randomised, double-blind, placebo-controlled, phase 3trial. Lancet 390(10111):2461-2471, 2017
 
4) Shitara K, Ozguroglu M, Bang YJ et al:Pembrolizumab vs paclitaxel for previously treated, advanced gastric or gastro-esoph-ageal junction cancer(KEYNOTE-061):a randomised, open-label, controlled, phase 3 trial. Lancet 392(10142):123-133, 2018
PubMed
5) Fuchs CS, Ozguroglu M, Bang YJ et al:Pembrolizumab versus paclitaxel for previ-ously treated PD-L1-positive advanced gas-tric or gastroesophageal junction cancer:2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer 25:197-206, 2022
PubMed
6) Shitara K, Van Cutsem E, Bang YJ et al:Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer:The KEY-NOTE-062 phase 3 randomized clinicaltrial. JAMA Oncol 6:1571-1580, 2020
 
7) Bang YJ, Ruiz EY, Van Custem E et al:Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer:primary analysis of JAV-ELIN Gastric 300. Ann Oncol 29:2052-2060, 2018
 
8) Moehler M, Dvorkin M, Boku N et al:Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers:Results from JAVELIN Gastric 100. J Clin Oncol. November 16, 2020
 
9) Moehler M, Shitara K, Garrido M et al:Nivolumab(nivo)plus chemotherapy(chemo)versus chemo as first-line(1L)treatment for advanced gastric cancer/gas-troesophageal junction cancer(GC/GEJC)/esophageal adenocarcinoma(EAC):First results of the CheckMate-649 study. Annals of Oncology 31(S4):S1191, 2020
 
10) Janjigian YY, Shitara K, Moehler M et al:First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma(CheckMate 649):a randomised, open-label, phase 3 trial. Lancet 398(10294):27-40, 2021
PubMed
11) Boku N, Ryu MH, Kato K et al:Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gas-tric/gastroesophageal junction cancer:interim results of a randomized, phase II trial(ATTRACTION-4). Ann Oncol 30:250-258, 2019
 
12) Chung HC, Bang YJ, S Fuchs C et al:First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer:KEY-NOTE-811. Future Oncol 17:491-501, 2021
 
13) Sakuramoto S, Sasako M, Yamaguchi T et al:Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820, 2007
 
14) Bang YJ, Kim YW, Yang HK et al:Adju-vant capecitabine and oxaliplatin for gas-tric cancer after D2 gastrectomy(CLAS-SIC):a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315-321, 2012
 
15) Yoshida K, Kodera Y, Kochi M et al:Ad-dition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer:Interim analysis of JAC-CRO GC-07, a randomized controlled trial. J Clin Oncol 37:1296-1304, 2019
 
P.36 掲載の参考文献
1) Yoshida M, Yabuuchi Y, Kakushima N et al:The incidence of non-ampullary duo-denal cancer in Japan:the first analysis of a national cancer registry. J Gastroenterol Hepatol 36:1216-1221, 2021
 
2) Yamasaki Y, Takeuchi Y, Kanesaka T et al:Differentiation between duodenal neoplasms and non-neoplasms using mag-nifying narrow-band imaging-Do we still need biopsies for duodenal lesions? Dig Endosc 32:84-95, 2020
 
3) Nakayama A, Kato M, Takatori Y et al:How I do it:Endoscopic diagnosis for su-perficial non-ampullary duodenal epithelial tumors. Dig Endosc 32:417-424, 2020
 
4) Akazawa Y, Ueyama H, Tsuyama S et al:Endoscopic and clinicopathological fea-tures of superficial non-ampullary duode-nal tumor based on the mucin phenotypes. Digestion 102:663-670, 2021
 
5) Yahagi N, Kato M, Ocihai Y et al:Outcomes of endoscopic resection for superficial duodenal epithelial neoplasia. Gastrointest Endosc 88:676-682, 2018
 
6) Kinoshita S, Nishizawa T, Ochiai Y et al:Accuracy of biopsy for the preoperative di-agnosis of superficial nonampullary duode-nal adenocarcinoma. Gastrointest Endosc 86:329-332, 2017
 
7) Hamada K, Takeuchi Y, Ishikawa H et al:Safety of cold snare polypectomy for duodenal adenomas in familial adenomatous polyposis:a prospective exploratory study. Endoscopy 50:511-517, 2018
PubMed
8) Akimoto T, Kato M, Yahagi N:Severe acute pancreatitis following cold polyp-ectomy of the minor duodenal papilla in a case with pancreas divisum. Dig Endosc 32:151, 2020
 
9) Kato M, Takeuchi Y, Hoteya S et al:Outcomes of endoscopic resection for superficial duodenal tumors:10 years' experience in 18 Japanese high-volume centers. Endoscopy, 2021[online ahead of print]
 
10) Binmoeller KF, Shah JN, Bhat YM et al:"Underwater" EMR of sporadic laterally spreading nonampullary duodenal adeno-mas(with video). Gastrointest Endosc 78:496-502, 2013
 
11) Kiguchi Y, Kato M, Nakayama A et al:Feasibility study comparing underwater endoscopic mucosal resection and conven-tional endoscopic mucosal resection for su-perficial non-ampullary duodenal epithelial tumor < 20mm. Dig Endosc 32:753-760, 2020
 
12) Yamasaki Y, Uedo N, Akamatsu T et al:Non-recurrence rate of underwater EMR for <- 20-mm non-ampullary duodenal ad-enomas:a multicenter prospective study(D-UEMR study). Clin Gastroenterol Hep-atol, 2021[online ahead of print]
PubMed
13) Takatori Y, Kato M, Nakayama A et al:Case of duodenal tumor adjacent to the diverticulum that was resected by the tech-nique of partial submucosal injection com-bined with underwater endoscopic mucosal resection. Dig Dis 39:70-74, 2021
 
14) Takatori Y, Kato M, Masunaga T et al:Feasibility study of partial submucosal injection technique combining underwater EMR for superficial duodenal epithelial tumors. Dig Dis Sci, 2021[online ahead of print]
 
15) Kato M, Sasaki M, Mizutani M et al:Predictors of technical difficulty with duo-denal ESD. Endosc Int Open 7:E1755-E1760, 2019
 
16) Yahagi N, Nishizawa T, Sasaki M et al:Water pressure method for duodenal endoscopic submucosal dissection. Endos-copy 49:E227-E228, 2017
 
17) Kato M, Takatori Y, Sasaki M et al:Water pressure method for duodenal endoscopic submucosal dissection(with video). Gas-trointest Endosc 93:942-949, 2021
 
18) Miura Y, Shinozaki S, Hayashi Y:Duode-nal endoscopic submucosal dissection is feasible using the pocket-creation method. Endoscopy 49:8-14, 2017
 
19) Dohi O, Yoshida N, Naito Y et al:Efficacy and safety of endoscopic submucosal dis-section using a scissors-type knife with prophylactic over-the-scope clip closure for superficial non-ampullary duodenal epithe-lial tumors. Dig Endosc 32:904-913, 2020
 
20) Kato M, Ochiai Y, Fukuhara S et al:Clinical impact of closure of the mucosal defect after duodenal endoscopic sub-mucosal dissection. Gastrointest Endosc 89:87-93, 2018
 
21) Tsutsumi K, Kato M, Kakushima N et al:Efficacy of endoscopic preventive proce-dures to reduce delayed adverse events af-ter endoscopic resection of superficial non-ampullary duodenal epithelial tumors:a meta-analysis of observational comparative trials. Gastrointest Endosc 93:367-374. e3, 2021
 
22) Fukuhara S, Kato M, Iwasaki E et al:Management of perforation related to endoscopic submucosal dissection for superficial duodenal epithelial tumors. Gas-trointest Endosc 91:1129-1137, 2019
 
23) Mizutani M, Kato M, Sasaki M et al:Pre-dictors of technical difficulty for complete closure of mucosal defects after duodenal endoscopic resection. Gastrointest Endosc 94:786-794, 2021
 
24) Irino T, Nunobe S, Hiki N et al:Laparo-scopic-endoscopic cooperative surgery for duodenal tumors:a unique procedure that helps ensure the safety of endoscopic sub-mucosal dissection. Endoscopy 47:349-351, 2015
 
25) Nunobe S, Ri M, Yamazaki K et al:Safety and feasibility of laparoscopic and endo-scopic cooperative surgery for duodenal neoplasm:a retrospective multicenter study. Endoscopy 53:1065-1068, 2021
 
26) Fukuhara S, Kato M, Iwasaki E et al:External drainage of bile and pancreatic juice after endoscopic submucosal dissec-tion for duodenal neoplasm:Feasibility study(with video). Dig Endosc 33:977-984, 2021
 
27) Yoshimizu S, Kawachi H, Yamamoto Y et al:Clinicopathological features and risk factors for lymph node metastasis in early-stage non-ampullary duodenal adenocarci-noma. J Gastroenterol 55:754-762, 2020
 
P.42 掲載の参考文献
1) 糸井隆夫, 良沢昭銘, 潟沼朗生 他:内視鏡的乳頭切除術(endoscopic papillec-tomy:EP)診療ガイドライン. Gastroen-terological Endoscopy 63:451-480, 2021
 
2) Vanbiervliet G, Strijker M, Arvanitakis M et al:Endoscopic management of ampul-lary tumors:European Society of Gastro-intestinal Endoscopy(ESGE)Guideline. Endoscopy 53:429-448, 2021
 
3) Iwasaki E, Minami K, Itoi T et al:Impact of electrical pulse cut mode during endo-scopic papillectomy:Pilot randomized clinical trial. Dig Endosc 32:127-135, 2020
 
4) 日本肝胆膵外科学会, 胆道癌診療ガイドライン作成委員会 編:胆道癌診療ガイドライン(改訂第3版). 医学図書出版, 2019
 
5) 日本肝胆膵外科学会 編:胆道癌取扱い規約(第7版). 金原出版, 2021
 
6) Yamamoto K, Itoi T, Sofuni A et al:Ex-panding the indication of endoscopic papil-lectomy for T1a ampullary carcinoma. Dig Endosc 31:188-196, 2019
 
7) Kawashima H, Ohno E, Ishikawa T et al:Endoscopic papillectomy for ampullary ad-enoma and early adenocarcinoma:Analy-sis of factors related to treatment outcome and long-term prognosis. Dig Endosc 33:858-869, 2021
 
8) Tanaka H, Kawashima H, Ohno E et al:Immunohistochemical staining for IMP3 in patients with duodenal papilla tumors:assessment of the potential for diagnosing endoscopic resectability and predicting prognosis. BMC Gastroenterol 21:224, 2021
PubMed
9) Kim HG, Park MS, Sung JY et al:Tumor-specific expression of insulin-like growth factor II mRNA-binding protein 3 indepen-dently predicts worse survival of patients with adenocarcinoma of the ampulla of Vater. Anticancer Res 39:4947-4955, 2019
 
10) Yamamoto K, Itoi T, Nagata N et al:Novel method for evaluating the indication for endoscopic papillectomy in patients with ampullary adenocarcinoma. Sci Rep 11:600, 2021
PubMed
11) Wang P, Jiang C, Wang Y et al:Outcome of a novel modified endoscopic papillec-tomy for duodenal major papilla adenoma. Surg Endosc 34:5160-5167, 2020
 
12) Takahara N, Tsuji Y, Nakai Y et al:A novel technique of endoscopic papillec-tomy with hybrid endoscopic submucosal dissection for ampullary tumors:A proof-of-concept study(with video). J Clin Med 9:2671, 2020
 
13) Fukuhara S, Kato M, Iwasaki E et al:External drainage of bile and pancreatic juice after endoscopic submucosal dissec-tion for duodenal neoplasm:Feasibility study(with video). Dig Endosc 33:977-984, 2021
 
14) Yamazaki T, Uchida D, Yamasaki Y et al:Underwater endoscopic papillectomy using double-balloon endoscopy. Endos-copy 52:E55-E56, 2020
 
15) Okano N, Igarashi Y, Ito K et al:Efficacy of hypertonic saline-epinephrine local injection around the anal side before endo-scopic papillectomy for ampullary tumors. Clin Endosc 54:706-712, 2021
 
16) Yang JK, Hyun JJ, Lee TH et al:Can pro-phylactic argon plasma coagulation reduce delayed post-papillectomy bleeding? A prospective multicenter trial. J Gastroen-terol Hepatol 36:467-473, 2021
 
17) Kagawa K, Kubota K, Kurita Y et al:Effect of preventive closure of the frenu-lum after endoscopic papillectomy:A prospective pilot study. J Gastroenterol Hepatol 35:374-379, 2020
 
18) Takahashi K, Ozawa E, Yasuda I et al:Predictive factor of recurrence after en-doscopic papillectomy for ampullary neo-plasms. J Hepatobiliary Pancreat Sci 28:625-634, 2021
 
19) Tringali A, Valerii G, Boskoski I et al:En-doscopic snare papillectomy for adenoma of the ampulla of Vater:Long-term results in 135 consecutive patients. Dig Liver Dis 52:1033-1038, 2020
 
20) Sahar N, Krishnamoorthi R, Kozarek RA et al:Long-term outcomes of endoscopic papillectomy for ampullary adenomas. Dig Dis Sci 65:260-268, 2020
PubMed
21) Sakai A, Tsujimae M, Masuda A et al:Clinical outcomes of ampullary neoplasms in resected margin positive or uncertain cases after endoscopic papillectomy. World J Gastroenterol 25:1387-1397, 2019
PubMed
P.49 掲載の参考文献
1) Nakamura M, Watanabe K, Ohmiya N et al:Tag-less patency capsule for sus-pected small bowel stenosis:Nationwide multicenter prospective study in Japan.Dig Endosc 33:151-161, 2021
 
2) Nakamura M, Yano T, Esaki M et al:Nov-el ultrathin double-balloon endoscopy for the diagnosis of small-bowel diseases:a multicenter nonrandomized study. Endos-copy 53:802-814, 2021
 
3) Haneda R, Sato S, Ohno K et al:Useful-ness of virtual enteroscopy for the detec-tion of small polypoid lesion in the small bowel, a case report. Int J Surg Case Rep 67:5-8, 2020
 
4) Yoo AY, Lee BJ, Kim WS et al:Clini-copathological features of small bowel tumors diagnosed by video capsule endos-copy and balloon-assisted enteroscopy:A single center experience. Clin Endosc 54:85-91, 2021
 
5) Zhang C, Hong L, Zhang T et al:Clini-cal characteristics of small bowel tumors diagnosed by double-balloon endoscopy:Experience from a Chinese tertiary hospi-tal. Turk J Gastroenterol 31:30-35, 2021
 
6) Demeester J, Dewint P, Schauvliege L et al:Capsule endoscopy:diagnosis of intestinal localisation of systemic follicular B-cell non-Hodgkin lymphoma. Acta Gas-troenterol Belg 83:73-75, 2020
 
7) Osaki Y, Kawaratani H, Kachi H et al:Small intestinal follicular lymphoma in-duced by methotrexate:a case report. BMC Gastroenterol 21:280, 2021
PubMed
8) Kogo H, Shimanuki K, Iwao T et al:Small bowel GIST with hemorrhagic shock diag-nosed by capsule endoscopy and double-balloon endoscopy, angiography-guided hemostasis, and laparoscopic-assisted resection. Clin Case Rep 9:e04240, 2021
 
9) Kataoka M, Saitoh T, Kawashima K et al:Primary extragastrointestinal stromal tu-mor of greater omentum with intraperito-neal bleeding. Intern Med 60:3413-3419, 2021
 
10) Martinez-Alcala A, Fry LC, Kroner T et al:Endoscopic spectrum and practical classification of small bowel gastrointes-tinal stromal tumors(GISTs)detected during double-balloon enteroscopy. Endosc Int Open 9:E507-E512, 2021
 
11) Endo K, Kawamura K, Murakami K et al:A case of jejunal solitary Peutz-Jeghe-rs polyp with intussusception identified by double-balloon enteroscopy. Clin J Gastro-enterol 13:1129-1135, 2020
 
12) Moyon FX, Molina GA, Romero K et al:Laparoscopy and intraoperative enteros-copy, a helpful tool in a rare tumor(inflam-matory fibroid polyp)of the small bowel.A case report. Ann Med Surg(Lond) 66:102355, 2021
 
13) Al-Tkrit A, Aneeb M, Mekaiel A et al:Cavernous hemangioma:A rare cause of massive lower gastrointestinal bleeding.Cureus 12:e10075, 2020
PubMed
14) Sinha A, Johal AS, Khurana A et al:Retrograde NaviAid enteroscopy-assisted resection of distal small bowel hamartoma-tous polyps. Cureus 12:e11962, 2020
PubMed
15) Yamamoto M, Iwamoto K, Suzuki R et al:Laparoscopic-assisted disinvagination and polypectomy for multiple intussuscep-tions induced by small intestinal polyps in patients with Peutz-Jeghers syndrome:a case report. World J Surg Oncol 19:22, 2021
 
16) Stasinos I, Kamperidis N, Murino A et al:Single incision laparoscopic assisted double balloon enteroscopy:a novel tech-nique to manage small bowel pathology. Surg Endosc 34:2773-2779, 2020
 
17) Perrod G, Samaha E, Perez-Cuadrado-Robles E et al:Small bowel polyp resec-tion using device-assisted enteroscopy in Peutz-Jeghers Syndrome:Results of a specialised tertiary care centre. United European Gastroenterol J 8:204-210, 2020
 
18)Khurelbaatar T, Sakamoto H, Yano T et al:Endoscopic ischemic polypectomy for small-bowel polyps in patients with Peutz-Jeghers syndrome. Endoscopy 53:744-748, 2021
PubMed
19) Suwa T, Imai K, Hotta K et al:Under-water ischemic polypectomy for multiple small bowel polyps in a patient with Peu-tz-Jeghers syndrome. Am J Gastroenterol 116:452, 2021
 
20) Li BR, Sun T, Li J et al:Primary experi-ence of small bowel polypectomy with balloon-assisted enteroscopy in young pe-diatric Peutz-Jeghers syndrome patients. Eur J Pediatr 179:611-617, 2020
 
21) Aoyama T, Fukumoto A, Shigita K et al:Successful endoscopic sclerotherapy using polidocanol for small bowel hemangioma. Intern Med 59:1727-1730, 2020
PubMed
22) Chen HY, Ning SB, Yin X et al:Balloon-assisted endoscopic submucosal dissection for treating small intestinal lipomas:Re-port of two cases. World J Clin Cases 9:1631-1638, 2021
 
P.54 掲載の参考文献
1) 日本消化器病学会 編:炎症性腸疾患(IBD)診療ガイドライン 2020(改訂第2版). 南江堂, 2020
 
2) 潰瘍性大腸炎・クローン病診断基準・治療指針. 令和2年度改訂版. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和2年度分担研究報告書. (令和3年3月31日公開)
 
3) Peyrin-Biroulet L, Sandborn W, Sands BE et al:Selecting therapeutic targets in inflammatory bowel disease(STRIDE):Determining therapeutic goals for treat-to-target. Am J Gastroenterol 110:1324-1338, 2015
PubMed
4) Turner D, Ricciuto A, Lewis A et al:STRIDE-II:An update on the Selecting Therapeutic Targets in Inflammatory Bowel disease(STRIDE)initiative of the International Organization for the Study of IBD(IOIBD):Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160:1570-1583, 2021
 
5) Jangi S, Holmer AK, Dulai PS et al:Risk of relapse in patients with ulcerative colitis with persistent endoscopic healing:A du-rable treatment endpoint. J Crohns Colitis 15:567-574, 2021
 
6) Bossuyt P, Bisschops R, Vermeire S et al:Variability in the distribution of histologi-cal disease activity in the colon of patients with ulcerative colitis. J Crohns Colitis 15:603-608, 2021
 
7) Cushing KC, Tan W, Alpers DH et al:Complete histologic normalisation is asso-ciated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Alimentary Phar-macol Ther 51:347-355, 2020
 
8) Naganuma M, Kobayashi T, Nasuno M et al:Significance of conducting 2 types of fecal tests in patients with ulcerative coli-tis. Clin Gastroenterol Hepatol 18:1102-1111. e5, 2020
 
9) Dulai PS, Battat R, Barsky M et al:In-corporating fecal calprotectin into clinical practice for patients with moderate-to-severely active ulcerative colitis treated with biologics or small-molecule inhibitors. Am J Gastroenterol 115:885-894, 2020
PubMed
10) McKechnie T, Lee Y, Kruse C et al:The role of fecal calprotectin in the diagnosis of acute pouchitis following IPAA for ulcer-ative colitis:a systematic clinical review. Int J Colorectal Dis 35:1619-1628, 2020
 
11) Shinzaki S, Matsuoka K, Tanaka H et al:Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab:PLANET study. J Gastroenterol 56:560-569, 2021
PubMed
12) Tsai L, Ma C, Dulai PS et al:Contempo-rary risk of surgery in patients with ulcer-ative colitis and Crohn's disease:A meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol 19:2031-2045. e11, 2021
 
13) Cha JM, Park SH, Rhee KH et al:Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. Gut 69:1432-1440, 2020
 
14) Salameh R, Kirchgesner J, Allez M et al:Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther 51:1096-1104, 2020
PubMed
15) Matsuoka K, Igarashi A, Sato N et al:Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use:Analy-sis using Japanese claims data from 2006 to 2016. J Crohns Colitis 15:358-366, 2021
 
16) Kobayashi T, Motoya S, Nakamura S et al:Discontinuation of infliximab in pa-tients with ulcerative colitis in remission(HAYABUSA):a multicentre, open-label, randomised controlled trial. Lancet Gastro-enterol Hepatol 6:429-437, 2021
 
17) Cheifetz AS, Abreu MT, Afif W et al:A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflamma-tory bowel disease. Am J Gastroenterol 116:2014-2025, 2021
 
18) Hu A, Kotze PG, Burgevin A et al:Com-bination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gas-troenterol Hepatol 19:1366-1376. e2, 2021
 
19) Novello M, Stocchi L, Steele SR et al:Case-matched comparison of postoperative outcomes following surgery for inflam-matory bowel disease after exposure to vedolizumab vs other biologics. J Crohns Colitis 14:185-191, 2020
 
20) Sands BE, Colombel JF, Ha C et al:Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for car-diovascular risk and patient management. Inflamm Bowel Dis 27:797-808, 2021
 
21) Lichtenstein GR, Rogler G, Ciorba MA et al:Tofacitinib, an oral Janus kinase inhibi-tor:Analysis of malignancy(excluding nonmelanoma skin cancer)events across the ulcerative colitis Clinical Program. In-flamm Bowel Dis 27:816-825, 2021
 
22) Sandborn WJ, Ferrante M, Bhandari BR et al:Efficacy and safety of continued treat-ment with mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastro-enterol Hepatol 20:105-115. e14, 2022
 
23) Feagan BG, Danese S, Loftus EV Jr et al:Filgotinib as induction and maintenance therapy for ulcerative colitis(SELEC-TION):a phase 2b/3 double-blind, ran-domised, placebo-controlled trial. Lancet 397(10292):2372-2384, 2021
 
24) Ahmed W, Galati J, Kumar A et al:Dual biologic or small molecule therapy for treatment of inflammatory bowel disease:A systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2021[online ahead of print]
PubMed
25) SECURE-IBD Database. Coronavirus and IBD Reporting Database. https://covidibd.org/
 
26) Derikx LAAP, Lantinga MA, de Jong DJ et al:Clinical outcomes of covid-19 in pa-tients with inflammatory bowel disease:A nationwide cohort study. J Crohns Colitis 15:529-539, 2021
 
27) Singh S, Khan A, Chowdhry M et al:Risk of severe coronavirus disease 2019 in patients with inflammatory bowel dis-ease in the United States:A multicenter research network study. Gastroenterology 159:1575-1578. e4, 2020
 
28) Kochar B, Cai W, Cagan A et al:Pretreat-ment frailty is independently associated with increased risk of infections after im-munosuppression in patients with inflam-matory bowel diseases. Gastroenterology 158:2104-2111. e2, 2020
 
29) Kennedy NA, Goodhand JR, Bewshea C et al:Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treat-ed with infliximab. Gut 70:865-875, 2021
 
30) Wong SY, Dixon R, Martinez Pazos V et al:Serologic response to messenger RNA coronavirus disease 2019 vaccines in in-flammatory bowel disease patients receiv-ing biologic therapies. Gastroenterology 161:715-718. e4, 2021
 
P.60 掲載の参考文献
1) Assa A, Matar M, Turner D et al:Proac-tive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring. Gastroenterology 157:985-996. e2, 2019
 
2) Mak JWY, Tang W, Yip TCF et al:Stop-ping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. Ali-ment Pharmacol Ther 50:1195-1203, 2019
 
3) Ungaro RC, Limketkai BN, Jensen CB et al:Stopping mesalamine therapy in pa-tients with Crohn's disease starting biolog-ic therapy does not increase risk of adverse outcomes. Clin Gastroenterol Hepatol 18:1152-1160. e1, 2020
 
4) Faleck DM, Shmidt E, Huang R et al:Ef-fect of concomitant therapy with steroids and tumor necrosis factor antagonists for induction of remission in patients with Crohn's disease:A systematic review and pooled meta-analysis. Clin Gastroenterol Hepatol 19:238-245. e4, 2021
 
5) Murthy SK, Begum J, Benchimol EI et al:Introduction of anti-TNF therapy has not yielded expected declines in hospitalisa-tion and intestinal resection rates in in-flammatory bowel diseases:a population-based interrupted time series study. Gut 69:274-282, 2020
PubMed
6) Kopylov U, Hanzel J, Liefferinckx C et al:Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose sub-cutaneous maintenance therapy. Aliment Pharmacol Ther 52:135-142, 2020
 
7) Chapuis-Biron C, Kirchgesner J, Pariente B et al:Ustekinumab for perianal Crohn's disease:The BioLAP multicenter study from the GETAID. Am J Gastroenterol 115:1812-1820, 2020
 
8) Alric H, Amiot A, Kirchgesner J et al:The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther 51:948-957, 2020
PubMed
9) Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ et al:Ustekinum-ab for Crohn's disease:results of the ICC Registry, a nationwide prospective obser-vational cohort study. J Crohns Colitis 14:33-45, 2020
 
10) Yang E, Panaccione N, Whitmire N et al:Efficacy and safety of simultaneous treat-ment with two biologic medications in refractory Crohn's disease. Aliment Phar-macol Ther 51:1031-1038, 2020
 
11) Hisamatsu T, Kato S, Kunisaki R et al:Withdrawal of thiopurines in Crohn's dis-ease treated with scheduled adalimumab maintenance:a prospective randomised clinical trial(DIAMOND2). J Gastroen-terol 54:860-870, 2019
 
12) Roblin X, Williet N, Boschetti G et al:Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies:a pro-spective randomised trial. Gut 69:1206-1212, 2020
 
13) Banerjee R, Ravikanth VV, Pal P et al:NUDT15 C415T variant compared with TPMT genotyping in predicting azathi-oprine-induced leucopenia:prospective analysis of 1014 inflammatory bowel dis-ease patients in India. Aliment Pharmacol Ther 52:1683-1694, 2020
 
14) Mesonero F, Castro-Poceiro J, Benitez J Met al:Effectiveness and safety of metho-trexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α:results from the ENEIDA registry. Ali-ment Pharmacol Ther 53:1021-1029, 2021
 
15) Panes J, D'Haens GR, Higgins PDR et al:Long-term safety and tolerability of oral tofacitinib in patients with Crohn's dis-ease:results from a phase 2, open-label, 48-week extension study. Aliment Pharmacol Ther 49:265-276, 2019
 
16) Sandborn WJ, Feagan BG, Loftus EV et al:Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology 158:2123-2138. e8, 2020
 
17) Rodriguez-Lago I, Castro-Poceiro J, Fernan-dez-Clotet A et al:Tacrolimus induces short-term but not long-term clinical re-sponse in inflammatory bowel disease. Ali-ment Pharmacol Ther 51:870-879, 2020
 
18) Feagan BG, Sandborn WJ, Danese S et al:Ozanimod induction therapy for pa-tients with moderate to severe Crohn's disease:a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 5:819-828, 2020
 
19) Shinzaki S, Matsuoka K, Tanaka H et al:Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab:PLANET study. J Gastroenterol 56:560-569, 2021
PubMed
20) Yanai S, Shinzaki S, Matsuoka K et al:Leucine-rich alpha-2 glycoprotein may be predictive of the adalimumab trough level and antidrug antibody development for patients with inflammatory bowel disease:A sub-analysis of the PLANET study. Digestion 102:929-937, 2021
PubMed
21) Kawamoto A, Takenaka K, Hibiya S et al:Serum leucine-rich α2 glycoprotein:A novel biomarker for small bowel mucosal activity in Crohn's disease. Clin Gastroen-terol Hepatol, 2021[online ahead of print]
 
22) Kennedy NA, Heap GA, Green HD et al:Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active lumi-nal Crohn's disease:a prospective, multi-centre, cohort study. Lancet Gastroenterol Hepatol 4:341-353, 2019
 
23) Bertani L, Fornai M, Fornili M et al:Serum oncostatin M at baseline predictsmucosal healing in Crohn's disease pa-tients treated with infliximab. Aliment Pharmacol Ther 52:284-291, 2020
 
24) Ding NS, McDonald JAK, Perdones-Montero A et al:Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease. J Crohns Colitis 14:1090-1102, 2020
PubMed
25) Oliva S, Aloi M, Viola F et al:A treat to target strategy using panenteric cap-sule endoscopy in pediatric patients with Crohn's disease. Clin Gastroenterol Hepa-tol 17:2060-2067. e1, 2019
 
26) Takenaka K, Fujii T, Suzuki K et al:Small bowel healing detected by endoscopy in patients with Crohn's disease after treat-ment with antibodies against tumor ne-crosis factor. Clin Gastroenterol Hepatol 18:1545-1552, 2020
 
27) Christensen B, Erlich J, Gibson PR et al:Histologic healing is more strongly associ-ated with clinical outcomes in ileal Crohn's disease than endoscopic healing. Clin Gas-troenterol Hepatol 18:2518-2525. e1, 2020
 
28) Potdar AA, Dube S, Naito T et al:Altered intestinal ACE2 levels are associated with inflammation, severe disease, and response to anti-cytokine therapy in inflammatory bowel disease. Gastroenterology 160:809-822. e7, 2021
 
29) Toyonaga T, Araba KC, Kennedy MM et al:Increased colonic expression of ACE2 associates with poor prognosis in Crohn's disease. Sci Rep 11:13533, 2021
PubMed
P.66 掲載の参考文献
1) 日本消化器病学会 編:大腸ポリープ診療ガイドライン 2020(改訂第2版). 2020
 
2) 斎藤 豊, 岡 志郎, 河村卓二 他:大腸内視鏡スクリーニングとサーベイランスガイドライン. Gastroenterol Endosc 62:1520-1560, 2020
 
3) 浦岡俊夫, 滝沢耕平, 田中信治 他:大腸cold polypectomy ガイドライン(大腸ESD/EMRガイドライン追補). Gastroen-terol Endosc 63:1147-1158, 2021
 
4) Tanaka S, Saitoh Y, Matsuda T et al:Evidence-based clinical practice guide-lines for management of colorectal polyps. J Gastroenterol 56:323-335, 2021
 
5) Saito Y, Oka S, Kawamura T et al:Colo-noscopy screening and surveillance guide-lines. Dig Endosc 33:486-519, 2021
 
6) Sekiguchi M, Kakugawa Y, Ikematsu H et al:Risk stratification score improves sensitivity for advanced colorectal neopla-sia in colorectal cancer screening:The Oshima Study Workgroup. Clin Transl Gastroenterol 12:e00319, 2021
 
7) Crockett SD, Nagtegaal ID:Terminol-ogy, molecular features, epidemiology, and management of serrated colorectal neoplasia. Gastroenterology 157:949-966. e4, 2019
 
8) 橋本大輝, 水口康彦, 斎藤 豊 他:Super-ficially Serrated Adenoma(SuSA). 胃と腸 55:1605-1614, 2020
 
9) Klair JS, Ashat M, Johnson D et al:Ser-rated polyp detection rate and advanced adenoma detection rate from a US multi-center cohort. Endoscopy 52:61-67, 2020
 
10) Wang P, Berzin TM, Glissen Brown JR et al:Real-time automatic detection sys-tem increases colonoscopic polyp and adenoma detection rates:a prospective randomised controlled study. Gut 68:1813-1819, 2019
 
11) Wang P, Liu P, Glissen Brown JR et al:Lower adenoma miss rate of computer-aided detection-assisted colonoscopy vs routine white-light colonoscopy in a pro-spective tandem study. Gastroenterology 159:1252-1261. e5, 2020
 
12) Bhurwal A, Rattan P, Sarkar A et al:A comparison of 9-min colonoscopy with-drawal time and 6-min colonoscopy with-drawal time:A systematic review and meta-analysis. J Gastroenterol Hepatol 36:3260-3267, 2021
 
13) Atkinson NSS, Ket S, Bassett P et al:Narrow-band imaging for detection of neoplasia at colonoscopy:A meta-analysis of data from individual patients in random-ized controlled trials. Gastroenterology 157:462-471, 2019
 
14) Paggi S, Radaelli F, Senore C et al:Linked-color imaging versus white-light colonoscopy in an organized colorectal cancer screening program. Gastrointest Endosc 92:723-730, 2020
 
15) Shinozaki S, Kobayashi Y, Hayashi Y et al:Colon polyp detection using linked color imaging compared to white light imaging:Systematic review and meta-analysis. Dig Endosc 32:874-881, 2020
PubMed
16) Leung WK, Guo CG, Ko MKL et al:Linked color imaging versus narrow-band imaging for colorectal polyp detection:a prospective randomized tandem colonos-copy study. Gastrointest Endosc 91:104-112. e5, 2020
 
17) Yoshida N, Mano Y, Matsuda T et al:Complications of colonoscopy in Japan:An analysis using large-scale health insur-ance claims data. J Gastroenterol Hepatol 36:2745-2753, 2021
 
18) Inoue K, Okuda T, Oka K et al:Effects of L-menthol and carbon dioxide on the adenoma detection rate during colonos-copy:L-menthol and carbon dioxide on colonoscopy. Digestion 101:323-331, 2020
 
19) Ito R, Ikematsu H, Murano T et al:Diag-nostic ability of Japan Narrow-Band Imag-ing Expert Team classification for colorec-tal lesions by magnifying endoscopy with blue laser imaging versus narrow-band imaging. Endosc Int Open 9:E271-E277, 2021
 
20) Kawamura T, Takeuchi Y, Yokota I et al:Indications for cold polypectomy stratified by the colorectal polyp size:A systematic review and meta-analysis. J Anus Rectum Colon 4:67-78, 2020
 
21) Shichijo S, Takeuchi Y, Kitamura M et al:Does cold snare polypectomy com-pletely resect the mucosal layer? A pro-spective single-center observational trial. J Gastroenterol Hepatol 35:241-248, 2020
 
22) Djinbachian R, Iratni R, Durand M et al:Rates of incomplete resection of 1- to 20-mm colorectal polyps:A systematic re-view and meta-analysis. Gastroenterology 159:904-914. e12, 2020
 
23) Yoshida N, Inoue K, Dohi O et al:Ef-ficacy of precutting endoscopic mucosal resection with full or partial circumferen-tial incision using a snare tip for difficult colorectal lesions. Endoscopy 51:871-876, 2019
 
24) Imai K, Hotta K, Ito S et al:Tip-in en-doscopic mucosal resection for 15- to 25-mm colorectal adenomas:A single-center, randomized controlled trial(STAR Trial). Am J Gastroenterol 116:1398-1405, 2021
 
25) Yamashina T, Uedo N, Akasaka T et al:Comparison of underwater vs conven-tional endoscopic mucosal resection of intermediate-size colorectal polyps. Gastro-enterology 157:451-461. e2, 2019
 
26) Yen AW, Leung JW, Wilson MD et al:Underwater versus conventional endo-scopic resection of nondiminutive nonpe-dunculated colorectal lesions:a prospec-tive randomized controlled trial(with video). Gastrointest Endosc 91:643-654. e2, 2020
 
27) Pohl H, Grimm IS, Moyer MT et al:Clip closure prevents bleeding after endoscopic resection of large colon polyps in a ran-domized trial. Gastroenterology 157:977-984. e3, 2019
 
28) 木村一雄, 中村正人, 石原正治 他:2020年JCSガイドライン フォーカスアップデート版:冠動脈疾患患者における抗血栓療法. 2020
 
29) Shono T, Oyama S, Oda Y et al;Kuma-moto Colon Cancer Study Group:Risk stratification of advanced colorectal neo-plasia after baseline colonoscopy:Cohort study of 17 Japanese community practices. Dig Endosc 32:106-113, 2020
 
30) Matsuda T, Fujii T, Sano Y et al:Ran-domised comparison of postpolypectomysurveillance intervals following a two-round baseline colonoscopy:the JapanPolyp Study Workgroup. Gut 70:1469-1478, 2020
 
P.73 掲載の参考文献
1) 大腸癌研究会 編:大腸癌治療ガイドライン 医師用 2019年版. 金原出版, 2019
 
2) 田中信治, 樫田博史, 斉藤 豊 他:大腸ESD/EMRガイドライン(第2版). Gas-troenterol Endosc 61:1323-1337, 2019
 
3) 日本消化器病学会 編:大腸ポリープ診療ガイドライン2020(改訂第2版). 南江堂, 2020
 
4) Saito Y, Oka S, Kawamura T et al:Colo-noscopy screening and surveillance guide-lines. Dig Endosc 33:486-519, 2021
 
5) Nakahara R, Amano Y, Murakami D et al:Relationship between colonic diver-ticulosis and colon neoplasms in Japanese patients. Dig Endosc 33:418-424, 2021
 
6) Atkinson NSS, Ket S, Bassett P et al:Narrow-band imaging for detection of neoplasia at colonoscopy:A meta-analysis of data from individual patients in random-ized controlled trials. Gastroenterology 157:462-471, 2019
 
7) Shinozaki S, Kobayashi Y, Hayashi Y et al:Colon polyp detection using linked color imaging compared to white light imaging:Systematic review and meta-analysis. Dig Endosc 32:874-881, 2020
PubMed
8) Murano T, Ikematsu H, Shinmura K et al:Endoscopic prediction of advanced his-tology in colorectal lesions sized < 10mm using the Japan Narrow-band Imaging Ex-pert Team classification. Dig Endosc 32:785-790, 2020
 
9) Hosotani K, Imai K, Hotta K et al:Diagnos-tic performance for T1 cancer in colorectal lesions >- 10mm by optical characterization using magnifying narrow-band imaging combined with magnifying chromoendos-copy;implications for optimized stratifica-tion by Japan Narrow-band Imaging Expert Team classification. Dig Endosc 33:425-432, 2021
 
10) Yamasaki Y, Harada K, Yamamoto S et al:Blue laser imaging and linked color imaging improve the color difference value and visibility of colorectal polyps in under-water conditions. Dig Endosc 32:791-800, 2020
PubMed
11) van de Ven SEM, Backes Y, Hilbink M et al:Periprocedural adverse events after endoscopic resection of T1 colorectal car-cinomas. Gastrointest Endosc 91:142-152. e3, 2020
 
12) Spadaccini M, Albeniz E, Pohl H et al:Prophylactic clipping after colorectal en-doscopic resection prevents bleeding of large, proximal polyps:Meta-analysis of randomized trials. Gastroenterology 159:148-158. e11, 2020
 
13) Chen B, Du L, Luo L et al:Prophylac-tic clips to reduce delayed polypectomy bleeding after resection of large colorectal polyps:a systematic review and meta-analysis of randomized trials. Gastrointest Endosc 93:807-815, 2021
 
14) Chandan S, Khan SR, Kumar A et al:Efficacy and histologic accuracy of un-derwater versus conventional endoscopic mucosal resection for large(> 20mm)colorectal polyps:a comparative review and meta-analysis. Gastrointest Endosc 94:471-482. e9, 2021
 
15) Choi AY, Moosvi Z, Shah S et al:Un-derwater versus conventional EMR for colorectal polyps:systematic review and meta-analysis. Gastrointest Endosc 93:378-389, 2021
 
16) Inoue T, Nakagawa K, Yamasaki Y et al:Underwater endoscopic mucosal resection versus endoscopic submucosal dissection for 20-30 mm colorectal polyps. J Gastro-enterol Hepatol 36:2549-2557, 2021
 
17) Fukuda H, Takeuchi Y, Shoji A et al:Cu-rative value of underwater endoscopic mu-cosal resection for submucosally invasive colorectal cancer. J Gastroenterol Hepatol 36:2471-2478, 2021
 
18) Kato M, Hayashi Y, Fukuda H et al:Geri-atric nutritional risk index as a prognostic indicator in elderly patients with early colorectal cancer undergoing endoscopic submucosal dissection. Dig Endosc, 2021[online ahead of print]
 
19) Li B, Shi Q, Xu EP et al:Prediction of technically difficult endoscopic submucosal dissection for large superficial colorectal tumors:a novel clinical score model. Gas-trointest Endosc 94:133-144. e3, 2021
 
20) Imai K, Hotta K, Ito S et al:A risk-predic-tion model for en bloc resection failure or perforation during endoscopic submucosal dissection of colorectal neoplasms. Dig En-dosc 32:932-939, 2020
 
21) Bordillon P, Pioche M, Wallenhorst T et al:Double-clip traction for colonic endoscopic submucosal dissection:a multicenter study of 599 consecutive cases(with video). Gastrointest Endosc 94:333-343, 2021
PubMed
P.77 掲載の参考文献
1) 大腸癌研究会 編:大腸癌治療ガイドライン医師用 2019年版. 金原出版, 2019
 
2) Glynne-Jones R, Wyrwicz L, Tiret E et al:Rectal cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv22-iv40, 2017
 
3) Benson AB, Venook AP, Al-Hawary MM et al:NCCN Guidelines Insights:Rectal Cancer, Version 6.2020:Featured Updates to the NCCN Guidelines. J Natl Compr Cancer Netw 18:806-815, 2020
 
4) Kasi A, Abbasi S, Handa S et al:Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer:A sys-tematic review and meta-analysis. JAMA Netw Open 3:e2030097, 2020
 
5) Dossa F, Chesney TR, Acuna SA et al:A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation:a systematic review and meta-analysis. Lancet Gastroenterol Hepa-tol 2:501-513, 2017
 
6) Smith JJ, Strombom P, Chow OS et al:Assessment of a watch-and-wait strategy for rectal cancer in patients with a com-plete response after neoadjuvant therapy. JAMA Oncol 5:e185896, 2019
 
7) Fernandez LM, Sao Juliao GP, Figueiredo NL et al:Conditional recurrence-free sur-vival of clinical complete responders man-aged by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database:a retrospective, international, multicentre reg-istry study. Lancet Oncol 22:43-50, 2021
 
8) Kane C, Glynne-Jones R:Should we favour the use of 5 x 5 preoperative radiation in rectal cancer. Cancer Treat Rev 81:101908, 2019
 
9) Deng Y, Chi P, Lan P et al:Neoadjuvant modified FOLFOX6 with or without ra-diation versus fluorouracil plus radiation for locally advanced rectal cancer:Final results of the Chinese FOWARC Trial. J Clin Oncol 37:3223-3233, 2019
 
10) Bahadoer RR, Dijkstra EA, van Etten B et al:Short-course radiotherapy followed by chemotherapy before total mesorectal exci-sion(TME)versus preoperative chemo-radiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer(RAPIDO):a randomised, open-label, phase 3 trial. Lancet Oncol 22:29-42, 2021
 
11) Conroy T, Bosset JF, Etienne PL et al:Neoadjuvant chemotherapy with FOLFIRI-NOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer(UNICANCER-PRODIGE 23):a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702-715, 2021
 
12) Amelung FJ, Burghgraef TA, Tanis PJ et al:Critical appraisal of oncological safety of stent as bridge to surgery in left-sided obstructing colon cancer;a systematic review and meta-analysis. Crit Rev Oncol Hematol 131:66-75, 2018
PubMed
13) van Hooft JE, Veld JV, Arnold D et al:Self-expandable metal stents for obstruct-ing colonic and extracolonic cancer:European Society of Gastrointestinal En-doscopy(ESGE)Guideline - Update 2020. Endoscopy 52:389-407, 2020
 
14) Veld JV, Amelung FJ, Borstlap WAA et al:Comparison of decompressing stoma vs stent as a bridge to surgery for left-sided obstructive colon cancer. JAMA Surg 155:206-215, 2020
PubMed
15) Andre T, Meyerhardt J, Iveson T et al:Effect of duration of adjuvant chemo-therapy for patients with stage III colon cancer(IDEA collaboration):final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21:1620-1629, 2020
 
16) Iveson TJ, Sobrero AF, Yoshino T et al:Duration of adjuvant doublet chemo-therapy(3 or 6 months)in patients with high-risk stage II colorectal cancer. J Clin Oncol 39:631-641, 2021
PubMed
17) Hong YS, Kim SY, Lee JS et al:Oxaliplat-in-based adjuvant chemotherapy for rectal cancer after preoperative chemoradio-therapy(ADORE):Long-term results of a randomized controlled trial. J Clin Oncol 37:3111-3123, 2019
 
18) Kanemitsu Y, Shimizu Y, Mizusawa J et al:Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer(JCOG0603):A phase II or III random-ized controlled trial. J Clin Oncol 39:3789-3799, 2021
PubMed
19) Arnold D, Lueza B, Douillard JY et al:Prognostic and predictive value of prima-ry tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713-1729, 2017
 
20) Cremolini C, Loupakis F, Antoniotti C et al:FOLFOXIRI plus bevacizumab ver-sus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall surviv-al and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306-1315, 2015
 
21) Kopetz S, Grothey A, Yaeger R et al:Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381:1632-1643, 2019
PubMed
22) Tabernero J, Grothey A, Van Cutsem E et al:Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer:Updated survival results and sub-group analyses from the BEACON Study. J Clin Oncol 39:273-284, 2021
 
23) Pfeiffer P, Yilmaz M, Moller S et al:TAS-102 with or without bevacizumab in patients with chemorefractory meta-static colorectal cancer:an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21:412-420, 2020
PubMed
24) Cremolini C, Rossini D, Dell'Aquila E et al:Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan:A phase 2 single-arm clinical trial. JAMA Oncol 5:343-50, 2019
PubMed
25) Tie J, Cohen JD, Wang Y et al:Circulat-ing tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage iii colon cancer. JAMA Oncol 5:1710-1717, 2019
 
26) Wang Y, Li L, Cohen JD et al:Prognostic potential of circulating tumor DNA mea-surement in postoperative surveillance of nonmetastatic colorectal cancer. JAMA Oncol 5:1118-1123, 2019
 
27) Khakoo S, Carter PD, Brown G et al:MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adapta-tion in rectal cancer. Clin Cancer Res 26:183-192, 2020
 
28) Siena S, Di Bartolomeo M, Raghav K et al:Trastuzumab deruxtecan(DS-8201)in patients with HER2-expressing metastatic colorectal cancer(DESTINY-CRC01):a multicentre, open-label, phase 2 trial. Lancet Oncol 22:779-789, 2021
PubMed
29) Nakamura Y, Okamoto W, Kato T et al:Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal can-cer:a phase 2 trial. Nat Med 27:1899-1903, 2021
 
P.83 掲載の参考文献
1) Kato K, Cho BC, Takahashi M et al:Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previ-ous chemotherapy(ATTRACTION-3):a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:1506-1517, 2019
PubMed
2) Kojima T, Shah MA, Muro K et al:Ran-domized phase III KEYNOTE-181 Study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38:4138-4148, 2020
 
3) Sun JM, Shen L, Shah MA et al:Pem-brolizumab plus chemotherapy versus chemotherapy alone for first-line treat-ment of advanced oesophageal cancer(KEYNOTE-590):a randomised, placebo-controlled, phase 3 study. Lancet 398(10302):759-771, 2021
 
4) Kelly RJ, Ajani JA, Kuzdzal J et al:Adju-vant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384:1191-1203, 2021
PubMed
5) Janjigian YY, Shitara K, Moehler M et al:First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma(CheckMate 649):a randomised, open-label, phase 3 trial. Lancet 398(10294):27-40, 2021
PubMed
6) Fukuoka S, Hara H, Takahashi N et al:Regorafenib plus nivolumab in patients with advanced gastric or colorectal can-cer:An open-label, dose-escalation, and dose-expansion phase Ib trial(REGONI-VO, EPOC1603). J Clin Oncol 38:2053-2061, 2020
 
7) Kawazoe A, Fukuoka S, Nakamura Y et al:Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting(EPOC1706):an open-label, single-arm, phase 2 trial. Lancet Oncol 21:1057-1065, 2020
PubMed
8) Andre T, Shiu KK, Kim TW et al:Pem-brolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383:2207-2218, 2020
 
9) Casak SJ, Marcus L, Fashoyin-Aje L et al:FDA approval summary:Pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Can-cer Res 27:4680-4684, 2021
PubMed
10) Chida K, Kawazoe A, Kawazu M et al:A low tumor mutational burden and PTEN mutations are predictors of a negative re-sponse to PD-1 blockade in MSI-H/dMMR gastrointestinal tumors. Clin Cancer Res 27:3714-3724, 2021
 
11) Chalabi M, Fanchi LF, Dijkstra KK et al:Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon can-cers. Nat Med 26:566-576, 2020
 
12) Chen EX, Jonker DJ, Loree JM et al:Ef-fect of combined immune checkpoint inhi-bition vs best supportive care alone in pa-tients with advanced colorectal cancer:The Canadian Cancer Trials Group CO.26 Study. JAMA Oncol 6:831-838, 2020
 
P.89 掲載の参考文献
1)de Rooij WE, Barendsen ME, Warners MJ et al:Emerging incidence trends of eosinophilic esophagitis over 25 years:Results of a nationwide register-based pa-thology cohort. Neurogastroenterol Motil 33:e14072, 2021
PubMed
2) Lee K, Choe BH, Kang B et al:Nationwide multicenter study of eosinophilic esopha-gitis in Korean children. Pediatr Gastroen-terol Hepatol Nutr 23:231-242, 2020
 
3) Licari A, Votto M, Scudeller L et al:Epi-demiology of nonesophageal eosinophilic gastrointestinal diseases in symptomatic patients:A systematic review and meta-analysis. J Allergy Clin Immunol Pract 8:1994-2003. e2, 2020
 
4) Shah SC, Tepler A, Peek RM Jr et al:Association between Helicobacter pylori ex-posure and decreased odds of eosinophilic esophagitis - A systematic review and meta-analysis. Clin Gastroenterol Hepatol 17:2185-2198. e3, 2019
 
5) Limketkai BN, Shah SC, Hirano I et al:Epidemiology and implications of concur-rent diagnosis of eosinophilic oesopha-gitis and IBD based on a prospective population-based analysis. Gut 68:2152-2160, 2019
 
6) Dunn JLM, Shoda T, Caldwell JM et al:Consortium of Eosinophilic Gastrointes-tinal Disease Researchers(CEGIR):Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. J Allergy Clin Immu-nol 145:1629-1640. e4, 2020
 
7) Nakata A, Tanaka F, Nadatani Y et al:Classification of patients with esophageal eosinophilia by patterns of sensitization revealed by a diagnostic assay for multiple allergen-specific IgEs. J Gastroenterol 56:422-433, 2021
PubMed
8) Kitamura H, Tanaka F, Nadatani Y et al:Eosinophilic esophagitis and asymptomatic esophageal eosinophilia display similar im-munohistological profiles. J Clin Biochem Nutr 68:246-252, 2021
 
9) Min S, Shoda T, Wen T et al:Diagnostic merits of the eosinophilic esophagitis di-agnostic panel from a single esophageal biopsy. J Allergy Clin Immunol, 2021 [on-line ahead of print]
 
10) Shoda T, Wen T, Caldwell JM et al:Con-sortium of Eosinophilic Gastrointestinal Disease Researchers(CEGIR):Molecu-lar, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis:Multi-site study. J Allergy Clin Immunol 145:255-269, 2020
 
11) Cotton CC, Betancourt R, Randall CP et al:A model using clinical and endoscopic characteristics identifies patients at risk for eosinophilic esophagitis according to updated diagnostic guidelines. Clin Gastro-enterol Hepatol 19:1824-1834. e2, 2021
 
12) Chehade M, Kamboj AP, Atkins D et al:Diagnostic delay in patients with eo-sinophilic gastritis and/or duodenitis:A population-based study. J Allergy Clin Immunol Pract 9:2050-2059. e20, 2021
 
13) Laserna-Mendieta EJ, Casabona S, Guag-nozzi D et al:Efficacy of proton pump inhibitor therapy for eosinophilic oesopha-gitis in 630 patients:results from the EoE connect registry. Aliment Pharmacol Ther 52:798-807, 2020
 
14) Mougey EB, Nguyen V, Gutierrez-Jun-quera C et al:STAT6 variants associate with relapse of eosinophilic esophagitis in patients receiving long-term proton pump inhibitor therapy. Clin Gastroenterol Hepa-tol 19:2046-2053. e2, 2021
 
15) de Heer J, Miehlke S, Rosch T et al:Histo-logic and clinical effects of different topical corticosteroids for eosinophilic esophagi-tis:lessons from an updated meta-analysis of placebo-controlled randomized trials. Digestion 102:377-385, 2021
 
16) Straumann A, Lucendo AJ, Miehlke S et al:Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology 159:1672-1685. e5, 2020
 
17) Hirano I, Collins MH, Assouline-Dayan Y et al:RPC4046, a monoclonal antibody against IL13, reduces histologic and endo-scopic activity in patients with eosinophilic esophagitis. Gastroenterology 156:592-603. e10, 2019
 
18) Gann PH, Deaton RJ, McMahon N et al:An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis:Phase 2 trial results. J Allergy Clin Immunol 146:367-376. e3, 2020
 
19) Kakiuchi T, Nakayama A, Abe J et al:Ef-ficacy of a short-term six-food elimination diet and reintroduction therapy in pediat-ric eosinophilic gastroenteritis. Intern Med 59:1379-1385, 2020
 
20) Fang S, Song Y, Zhang S, Li C:Retrospec-tive study of budesonide in children with eosinophilic gastroenteritis. Pediatr Res 86:505-509, 2019
 
21) Kubo K, Kimura N, Mabe K et al:Eosino-philic gastroenteritis-associated duodenal ulcer successfully treated with crushed budesonide. Intern Med 59:2249-2254, 2020
 
22) Dellon ES, Peterson KA, Murray JA et al:Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med 383:1624-1634, 2020
PubMed
23) Dellon ES, Gonsalves N, Rothenberg ME et al:Determination of biopsy yield that optimally detects eosinophilic gastritis and/or duodenitis in a randomized trial of lirentelimab. Clin Gastroenterol Hepatol, 2021 [online ahead of print]
PubMed
24) Okimoto E, Ishimura N, Ishihara S:Clinical characteristics and treatment outcomes of patients with eosinophilic esophagitis and eosinophilic gastroenteritis. Digestion 102:33-40, 2021
PubMed
25) Jensen ET, Aceves SS, Bonis PA et al:High patient disease burden in a cross-sec-tional, multicenter contact registry study of eosinophilic gastrointestinal diseases. J Pediatr Gastroenterol Nutr 71:524-529, 2020
 
26)Yamamoto M, Nagashima S, Yamada Y et al:Comparison of nonesophageal eo-sinophilic gastrointestinal disorders with eosinophilic esophagitis:A nationwide survey. J Allergy Clin Immunol Pract 9:3339-3349. e8, 2021
 
27) Muir AB, Whelan KA, Dougherty MK et al:The potential for malignancy from atopic disorders and allergic inflamma-tion:A systematic review and meta-analy-sis. Clin Exp Allergy 50:147-159, 2020
 
28) Rojler L, Garber JJ, Roelstraete B et al:Mortality in eosinophilic esophagitis-a na-tionwide, population-based matched cohort study from 2005 to 2017. Ups J Med Sci 126. doi:10.48101/ujms.v126.7688. eCollection2021, 2021
 
29)Zevit N, Chehade M, Leung J et al:Eosinophilic esophagitis patients are not at increased risk of severe COVID-19:A report from a global registry. J Allergy Clin Immunol Pract, 2021 [online ahead of print]
 
P.95 掲載の参考文献
1) Mahurkar-Joshi S, Rankin CR, Videlock EJ et al:The colonic mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p are downregulated in irritable bowel syn-drome and are associated with barrier function and MAPK signaling. Gastroen-terology 160:2409-2422. e19, 2021
 
2) Peters S, Pascoe B, Wu Z et al:Campylo-bacter jejuni genotypes are associated with post-infection irritable bowel syndrome in humans. Commun Biol 4:1015, 2021
 
3) Wang X, Fukui H, Ran Y et al:Probiotic Bifidobacterium bifidum G9-1 has a preven-tive effect on the acceleration of colonic permeability and M1 macrophage popula-tion in maternally separated rats. Biomedi-cines 9:641, 2021
 
4) Mihindukulasuriya KA, Mars RAT, John-son AJ et al:Multi-omics analyses show disease, diet, and transcriptome interac-tions with the virome. Gastroenterology 161:1194-1207. e8, 2021
 
5) Salvo-Romero E, Martinez C, Lobo B et al:Overexpression of corticotropin-re-leasing factor in intestinal mucosal eosino-phils is associated with clinical severity in Diarrhea-Predominant Irritable Bowel Syndrome. Sci Rep 10:20706, 2020
 
6) Dothel G, Chang L, Shih W et al:μ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mu-cosa of irritable bowel syndrome patients. Neurogastroenterol Motil 31:e13688, 2019
 
7) Tsushima H, Zhang Y, Muratsubaki T et al:Oxytocin antagonist induced visceral pain and corticotropin-releasing hormone neuronal activation in the central nucleus of the amygdala during colorectal distention in mice. Neurosci Res 168:41-53, 2021
PubMed
8) Goyal O, Batta S, Nohria S et al:Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea-predominant irritable bowel syndrome:A prospective, randomized trial. J Gastroenterol Hepatol 36:2107-2115, 2021
 
9) Zhang Y, Feng L, Wang X et al:Low fermentable oligosaccharides, disaccha-rides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome:a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes. Am J Clin Nutr 113:1531-1545, 2021
 
10) Wang J, Yang P, Zhang L et al:A low-FODMAP diet improves the global symptoms and bowel habits of adult IBS patients:A systematic review and meta-analysis. Front Nutr 8:683191, 2021
 
11) Black CJ, Staudacher HM, Ford AC:Ef-ficacy of a low FODMAP diet in irritable bowel syndrome:systematic review and network meta-analysis. Gut, 2021[online ahead of print]
 
12) Hahn J, Choi J, Chang MJ:Effect of low FODMAPs diet on irritable bowel syn-dromes:A systematic review and meta-analysis of clinical trials. Nutrients 13:2460, 2021
 
13) Zheng T, Eswaran S, Photenhauer AL et al:Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying su-crase-isomaltase(SI)hypomorphic vari-ants. Gut 69:397-398, 2020
 
14) Bolte LA, Vich Vila A, Imhann F et al:Long-term dietary patterns are associated with pro-inflammatory and anti-inflamma-tory features of the gut microbiome. Gut 70:1287-1298, 2020
 
15) Xu H, Ma C, Zhao F et al:Adjunctive treatment with probiotics partially allevi-ates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur J Nutr 60:2553-2565, 2021
 
16) Skrzydlo-Radomanska B, Prozorow-Krol B, Cichoz-Lach H et al:The effective-ness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome:A randomized controlled study. Nutrients 13:756, 2021
 
17) Oh JH, Jang YS, Kang D et al:Efficacy and safety of new Lactobacilli probiotics for unconstipated irritable bowel syndrome:A randomized, double-blind, placebo-controlled trial. Nutrients 11:2887, 2019
PubMed
18) Wen Y, Li J, Long Q et al:The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome:A systematic review and meta-analysis based on seventeen random-ized controlled trials. Int J Surg 79:111-119, 2020
 
19) El-Salhy M, Hatlebakk JG, Gilja OH et al:Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 69:859-867, 2020
 
20) Lahtinen P, Jalanka J, Hartikainen A et al:Randomised clinical trial:faecal mi-crobiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Phar-macol Ther 51:1321-1331, 2020
 
21) Madsen AMA, Halkjar SI, Christensen AH et al:The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syn-drome:results from a randomised, double-blind, placebo-controlled study. Scand J Gastroenterol 56:761-769, 2021
 
22) Holvoet T, Joossens M, Vazquez-Castella-nos JF et al:Fecal microbiota transplan-tation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating:Short-and long-term results from a placebo-con-trolled randomized trial. Gastroenterology 160:145-157. e8, 2021
 
23) Sharbafchi MR, Afshar H, Adhamian P et al:Effects of venlafaxine on gastroin-testinal symptoms, depression, anxiety, stress, and quality of life in patients with the moderate-to-severe irritable bowel syndrome. J Res Med Sci 25:115, 2020
 
24) Khalilian A, Ahmadimoghaddam D, Saki S et al:A randomized, double-blind, pla-cebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. Biopsychosoc Med 15:3, 2021
 
25) Krouwel M, Farley A, Greenfield S et al:Systematic review, meta-analysis with subgroup analysis of hypnotherapy for irritable bowel syndrome, effect of inter-vention characteristics. Complement Ther Med 57:102672, 2021
 
26) Hasan SS, Whorwell PJ, Miller V et al:Six vs 12 sessions of gut-focused hypno-therapy for irritable bowel syndrome:A randomized trial. Gastroenterology 160:2605-2607. e3, 2021
 
P.102 掲載の参考文献
1) Guh AY, Mu Y, Winston LG et al:Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 382:1320-1330, 2020
PubMed
2) Kelly CP, LaMont JT:Clostridium difficile-more difficult than ever. N Engl J Med 359:1932-1940, 2008
PubMed
3) Song JH, Kim YS:Recurrent Clostridium difficile infection:Risk factors, treatment, and prevention. Gut Liver 13:16-24, 2019
PubMed
4) van Nood E, Vrieze A, Nieuwdorp M et al:Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407-415, 2013
PubMed
5) Kelly CR, Khoruts A, Staley C et al:Effect of fecal microbiota transplantation on re-currence in multiply recurrent Clostridium difficile infection:A randomized trial. Ann Intern Med 165:609-616, 2016
 
6) Quraishi MN, Widlak M, Bhala N et al:Systematic review with meta-analysis:the efficacy of faecal microbiota transplantation for the treatment of recurrent and refrac-tory Clostridium difficile infection. Aliment Pharmacol Ther 46:479-493, 2017
 
7) Furuya-Kanamori L, Doi SA, Paterson DL et al:Upper versus lower gastrointestinal delivery for transplantation of fecal micro-biota in recurrent or refractory Clostridium difficile infection:A collaborative analysisof individual patient data from 14 studies. J Clin Gastroenterol 51:145-150, 2017
 
8) Kassam Z, Lee CH, Yuan Y et al:Fecal microbiota transplantation for Clostridium difficile infection:systematic review and meta-analysis. Am J Gastroenterol 108:500-508, 2013
PubMed
9) Hui W, Li T, Liu W et al:Fecal microbiota transplantation for treatment of recurrent C. difficile infection:An updated random-ized controlled trial meta-analysis. PLoS One 14:e0210016, 2019
 
10) Ianiro G, Masucci L, Quaranta G et al:Randomised clinical trial:faecal micro-biota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther 48:152-159, 2018
 
11) Youngster I, Sauk J, Pindar C et al:Fe-cal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors:a ran-domized, open-label, controlled pilot study. Clin Infect Dis 58:1515-1522, 2014
 
12) Jiang ZD, Ajami NJ, Petrosino JF et al:Randomised clinical trial:faecal micro-biota transplantation for recurrent Clostri-dum difficile infection-fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther 45:899-908, 2017
 
13) Lee CH, Steiner T, Petrof EO et al:Fro-zen vs fresh fecal microbiota transplanta-tion and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection:A randomized clinical trial. JAMA 315:142-149, 2016
 
14) Kao D, Roach B, Silva M et al:Effect of oral capsule- vs colonoscopy-deliveredfecal microbiota transplantation on recur-rent Clostridium difficile infection:A ran-domized clinical trial. JAMA 318:1985-1993, 2017
 
15) 國島広之, 大毛宏喜, 鈴木広道 他:Clos-tridioides (Clostridium) difficile 感染症診療ガイドライン. 日化療会誌 66:645-690, 2018
 
16) Kelly CR, Fischer M, Allegretti JR et al:ACG clinical guidelines:prevention, diag-nosis, and treatment of Clostridioides dif-ficile infections. Am J Gastroenterol 116:1124-1147, 2021
 
17) McDonald LC, Gerding DN, Johnson S et al:Clinical practice guidelines for Clostridium difficile infection in adults and children:2017 update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA). Clin Infect Dis 66:e1-e48, 2018
 
18) Pittayanon R, Lau JT, Leontiadis GI et al:Differences in gut microbiota in pa-tients with vs without inflammatory bowel diseases:A systematic review. Gastroen-terology 158:930-946. e1, 2020
 
19) Quevrain E, Maubert MA, Michon C et al:Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65:415-425, 2016
PubMed
20) Pascal V, Pozuelo M, Borruel N et al:A microbial signature for Crohn's disease. Gut 66:813-822, 2017
PubMed
21) Kang CS, Ban M, Choi EJ et al:Extracellu-lar vesicles derived from gut microbiota, es-pecially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS One 8:e76520, 2013
 
22) Rajilic-Stojanovic M, de Vos WM:The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Micro-biol Rev 38:996-1047, 2014
 
23) Devkota S, Chang EB:Interactions be-tween diet, bile acid metabolism, gut mi-crobiota, and inflammatory bowel diseases. Dig Dis 33:351-356, 2015
 
24) Palmela C, Chevarin C, Xu Z et al:Adher-ent-invasive Escherichia coli in inflamma-tory bowel disease. Gut 67:574, 2018
 
25) Kaur L, Gordon M, Baines PA et al:Pro-biotics for induction of remission in ulcer-ative colitis. Cochrane Database Syst Rev 3:CD005573, 2020
 
26) Iheozor-Ejiofor Z, Kaur L, Gordon M et al:Probiotics for maintenance of remis-sion in ulcerative colitis. Cochrane Data-base Syst Rev 3:CD007443, 2020
 
27) Limketkai BN, Akobeng AK, Gordon M et al:Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 7:CD006634, 2020
PubMed
28) Rolfe VE, Fortun PJ, Hawkey CJ et al:Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 4:CD004826, 2006
PubMed
29) Imdad A, Nicholson MR, Tanner-Smith EE et al:Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 11:CD012774, 2018
 
30) Tang LL, Feng WZ, Cheng JJ et al:Clini-cal remission of ulcerative colitis after different modes of faecal microbiota trans-plantation:a meta-analysis. Int J Colorectal Dis 35:1025-1034, 2020
 
31) Caldeira LF, Borba HH, Tonin FS et al:Fecal microbiota transplantation in inflam-matory bowel disease patients:A system-atic review and meta-analysis. PLoS One 15:e0238910, 2020
 
32) Harbord M, Eliakim R, Bettenworth D et al:Third European evidence-based consen-sus on diagnosis and management of ulcer-ative colitis. Part 2:Current management. J Crohns Colitis 11:769-784, 2017
 
33) Torres J, Bonovas S, Doherty G et al:ECCO guidelines on therapeutics in Crohn's disease:medical treatment. J Crohns Colitis 14:4-22, 2019
 
34) Ko CW, Singh S, Feuerstein JD et al:American Gastroenterological Association Institute Clinical Guidelines Committee:AGA Clinical Practice Guidelines on the Management Of Mild-To-Moderate Ulcer-ative Colitis. Gastroenterology 156:748-764, 2019
 
35) Feuerstein JD, Ho EY, Shmidt E et al:AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology 160:2496-2508, 2021
PubMed
36) Rubin DT, Ananthakrishnan AN, Siegel CA et al:ACG clinical guideline:ulcer-ative colitis in adults. Am J Gastroenterol 114:384-413, 2019
 
37) Lichtenstein GR, Loftus EV, Isaacs KL et al:ACG clinical guideline:management of Crohn's disease in adults. Am J Gastro-enterol 113:481-517, 2018
 
38) Lamb CA, Kennedy NA, Raine T et al:British Society of Gastroenterology con-sensus guidelines on the management of inflammatory bowel disease in adults. Gut68(Suppl 3):s1-s106, 2019
 
P.107 掲載の参考文献
1) Mullady DK, Wang AY, Waschke KA:AGA clinical practice update on endo-scopic therapies for non-variceal upper gastrointestinal bleeding:Expert review. Gastroenterology 159:1120-1128, 2020
 
2) Jensen DM, Kovacs TOG, Ghassemi KA et al:Randomized controlled trial of over-the-scope clip as initial treatment of severe non-variceal upper gastrointestinal bleed-ing. Clin Gastroenterol Hepatol 19:2315-2323, 2021
 
3) Chen YI, Wyse J, Lu Y et al:TC-325 hemostatic powder versus current stan-dard of care in managing malignant GI bleeding:a pilot randomized clinical trial. Gastrointest Endosc 91:321-328, 2020
 
4) Alzoubaidi D, Hussein M, Rusu R et al:Outcomes from an international multi-center registry of patients with acute gastrointestinal bleeding undergoing en-doscopic treatment with Hemospray. Dig Endosc 32:96-105, 2020
 
5) Gralnek IM, Stanley AJ, Morris AJ et al:Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hem-orrhage(NVUGIH):European Society of Gastrointestinal Endoscopy(ESGE)Guideline-Update 2021. Endoscopy 53:300-332, 2021
 
6) 出血性潰瘍に対する内視鏡的止血治療は必要か?"消化性潰瘍診療ガイドライン 2020(改訂第3版)". 日本消化器病学会 編, 南江堂, pp6-7, 2020
 
7) Lau JYW, Yu Y, Tang RSY et al:Timing of endoscopy for acute upper gastrointes-tinal bleeding. N Engl J Med 382:1299-1308, 2020
 
8) Lau JYW:Management of acute upper gastrointestinal bleeding:Urgent versus early endoscopy. Dig Endosc, 2021[online ahead of print]
 
9) Guo CLT, Wong SH, Lau LHS et al:Tim-ing of endoscopy for acute upper gastroin-testinal bleeding:a territory-wide cohort study. Gut, 2021[online ahead of print]
 
10) Kamal F, Khan MA, Lee-Smith W et al:Role of routine second-look endos-copy in patients with acute peptic ulcer bleeding:meta-analysis of randomized controlled trials. Gastrointest Endosc 93:1228-1237. e5, 2021
 
11) Wong GLH, Lau LHS, Ching JYL et al:Prevention of recurrent idiopathic gastro-duodenal ulcer bleeding:a double-blind, randomised trial. Gut 69:652-657, 2020
PubMed
12) HCUP National(Nationwide)Inpatient Sample(NIS):Healthcare Cost and Utili-zation Project(HCUP), 2016-2017. Agen-cy for Healthcare Research and Quality(Rockville, MD) https://www.hcup-us.ahrq.gov/nisoverview.jsp
 
13) Wang Y, Bansal P, Li S et al:Dieulafoy's lesion of the upper GI tract:a comprehen-sive nationwide database analysis. Gastro-intest Endosc 94:24-34. e5, 2021
 
14) Oakland K, Chadwick G, East JE et al:Diagnosis and management of acute lower gastrointestinal bleeding:guidelines from the British Society of Gastroenterology. Gut 68:776-789, 2019
PubMed
15) Leeds JS, Jayaprakash A, Sanders DS et al:Management of acute lower GI bleed-ing:evidence-based medicine? Gut 69:1537-1538, 2020
 
16) Hu Q, Wu J, Ren Y et al:Degree of STING activation is associated with dis-ease outcomes. Gut 69:792-794, 2020
 
17) Oakland K, Kothiwale S, Forehand T et al:External validation of the Oakland score to assess safe hospital discharge among adult patients with acute lower gastrointestinal bleeding in the US. JAMA Netw Open 3:e209630, 2020
PubMed
18) Laursen SB, Oakland K, Laine L et al:ABC score:a new risk score that ac-curately predicts mortality in acute upper and lower gastrointestinal bleeding:an international multicentre study. Gut 70:707-716, 2021
 
19) Lee HS, Kang SH, Rou WS et al:Comput-ed tomography versus lower endoscopy as initial diagnostic method for evaluating patients with hematochezia at emergency room. Medicine(Baltimore)99:e20311, 2020
 
20) Kherad O, Restellini S, Almadi M et al:Systematic review with meta-analysis:limited benefits from early colonoscopy in acute lower gastrointestinal bleeding. Ali-ment Pharmacol Ther 52:774-788, 2020
 
21) Niikura R, Nagata N, Yamada A et al:Ef-ficacy and safety of early vs elective colo-noscopy for acute lower gastrointestinal bleeding. Gastroenterology 158:168-175. e6, 2020
 
22) Triantafyllou K, Gkolfakis P, Gralnek IM et al:Diagnosis and manage-ment of acute lower gastrointesti-nal bleeding:European Society of Gastro-intestinal Endoscopy (ESGE) Guideline. Endoscopy 53:850-868, 2021
 
23) Veitch AM, Radaelli F, Alikhan R et al:Endoscopy in patients on antiplatelet or anticoagulant therapy:British Society of Gastroenterology(BSG)and European Society of Gastrointestinal Endoscopy(ESGE)guideline update. Endoscopy 53:947-969, 2021
 
24) Mahady SE, Margolis KL, Chan A et al:Major GI bleeding in older persons using aspirin:incidence and risk factors in the ASPREE randomised controlled trial. Gut 70:717-724, 2021
 
25) Guo CG, Cheung KS, Zhang F et al:Inci-dences, temporal trends and risks of hos-pitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori:a territory-wide cohort study. Gut 69:445-452, 2020
PubMed
26) Tamari H, Aoyama T, Shigita K:The 'step-clipping' method:a guide for iden-tifying a previously bleeding colonic di-verticulum. Endosc Int Open 8:E64-E69, 2020
 
27) Kaise M, Nagata N, Ishii N et al:Epide-miology of colonic diverticula and recent advances in the management of colonic diverticular bleeding. Dig Endosc 32:240-250, 2020
 
28) Okamoto T, Nakamura K, Yamamoto K et al:Safety and effectiveness of endoscopic band ligation for colonic diverticular bleed-ing in elderly patients. Digestion 102:760-766, 2021
 
29) Sato Y, Yasuda H, Fukuoka A et al:De-layed perforation after endoscopic band li-gation for colonic diverticular hemorrhage. Clin J Gastroenterol 13:6-10, 2020
 
30) Ohmiya N:Management of obscure gastrointestinal bleeding:Comparison of guidelines between Japan and other countries. Dig Endosc 32:204-218, 2020
PubMed
P.114 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患克服対策研究事業「ベーチェット病に関する調査研究」平成21年度研究報告書, 2010
 
2) Hisamatsu T, Naganuma M, Matsuoka K et al:Diagnosis and management of intes-tinal Behcet's disease. Clin J Gastroenterol 7:205-212, 2014
 
3) 久松理一, 平井郁仁, 松本主之 他:腸管ベーチェット病診療コンセンサス・ステートメント案(2013年改訂). 厚生労働科学研究費補助金難治性疾患等克服研究事業 腸管希少疾患病群の疫学, 病態, 診断, 治療の相同性と相違性から見た包括的研究. 平成25年度総括研究報告書. pp32-37, 2014
 
4) 武藤徹一郎:いわゆる"Simple Ulcer"とは. 胃と腸 14:739-767, 1979
 
5) 渡辺英伸, 遠城寺宗知, 八尾恒良:回盲弁近傍の単純性潰瘍の病理. 胃と腸 14:749-767, 1979
 
6) Tada Y, Koarada S, Haruta Y et al:The association of Behcet's disease with myelodysplastic syndrome in Japan:a re-view of the literature. Clin Exp Rheumatol 24:S115-S119, 2006
 
7) Kimura S, Kuroda J, Akaogi T et al:Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis-Behcet's syndrome. Leuk Lymphoma 42:115-121, 2001
 
8) Kawabata H, Sawaki T, Kawanami T et al:Myelodysplastic syndrome complicat-ed with inflammatory intestinal ulcers:significance of trisomy 8. Intern Med 45:1309-1314, 2006
 
9) 岡部治弥, 崎村正弘:仮称"非特異性多発性小腸潰瘍症". 胃と腸 3:1539-1549, 1968
 
10) 崎村正弘:"非特異性多発性小腸潰瘍症"の臨床的研究:限局性腸炎との異同を中心として. 福岡医誌 61:318-340, 1970
 
11) Umeno J, Hisamatsu T, Esaki M et al:A hereditary enteropathy caused by muta-tions in the SLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet 11:e1005581, 2015
 
12) Umeno J, Esaki M, Hirano A et al:Clinical features of chronic enteropathy associ-ated with SLCO2A1 gene:a new entity clinically distinct from Crohn's disease. J Gastroenterol 53:907-915, 2018
 
13) Compton RF, Sandborn WJ, Yang H et al:A new syndrome of Crohn's disease and pachydermoperiostosis in a family. Gastroenterology 112:241-249, 1997
 
14) Uhlig HH, Schwerd T, Koletzko S et al:The diagnostic approach to monogenic very early onset inflammatory bowel dis-ease. Gastroenterology 147:990-1007. e3, 2014
 
15) Uhlig HH:Monogenic diseases associated with intestinal inflammation:implications for the understanding of inflammatory bowel disease. Gut 62:1795-1805, 2013
PubMed
16) Crowley E, Warner N, Pan J et al:Preva-lence and clinical features of inflammatory bowel diseases associated with monogenic variants, identified by whole-exome se-quencing in 1000 children at a single center. Gastroenterology 158:2208-2220, 2020
 
17) Uhlig HH, Charbit-Henrion F, Kotlarz D et al:Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease. A position paper from the Paediat-ric IBD Photo Group of European Society of Paediatric Gastroenterogy, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 72:456-473, 2021
 
18) Ouahed J, Kelsen JR, Spessott WA et al:Variants in STXBP3 are associated with very early onset inflammatory bowel dis-ease, bilateral sensorineural hearing loss and immune dysregulation. J Crohn Colitis 15:1908-1919, 2021
 
19) Norsa L, Berni Canani R, Duclaux-Loras R et al:Inflammatory bowel disease in pa-tients with congenital chloride diarrhoea. J Crohn Colitis 15:1679-1685, 2021
 
20) Zhang ZZ, Zhang Y, He T et al:Homozy-gous IL37 mutation associated with infan-tile inflammatory bowel disease. Proc Natl Acad Sci USA 118:e2009217118, 2021
 
21) Ziv A, Werner L, Konnikova L et al:An RTEL1 mutation links to infantile-onset ulcerative colitis and severe immunodefi-ciency. J Clin Immunol 40:1010-1019, 2020
 
22) Nambu R, Warner N, Mulder DJ et al:A systematic review of monogenic inflam-matory bowel disease. Clin Gastroenterol Hepatol, 2021[online ahead of print]
 
23) Brooke MA, Longhurst HJ, Plagnol V et al:Cryptogenic multifocal ulcerating stenosing enteritis associated with ho-mozygous deletion mutations in cytosolic phospholipase A2-α. Gut 63:96-104, 2014
 
24) Chang DK, Kim JJ, Choi H et al:Double balloon endoscopy in small intestinal Crohn's disease and other inflammatory diseases such as cryptogenic multifocal ulcerous stenosing enteritis(CMUSE). Gastrointest Endosc 66:S96-S98, 2007
PubMed
25) Perlemuter G, Guillevin L, Legman P et al:Cryptogenetic multifocal ulcerous ste-nosing enteritis:an atypical type of vas-culitis or a disease mimicking vasculitis. Gut 48:333-338, 2001
PubMed
26) Adler DH, Cogan JD, Phillips JA 3rd et al:Inherited human cPLA2α deficiency is associated with impaired eicosanoid bio-synthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest 118:2121-2131, 2008
 
P.119 掲載の参考文献
1) Sperber AD, Bangdiwala SI, Drossman DA et al:Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 160:99-114. e3, 2021
 
2) Sperber AD, Freud T, Aziz I et al:Greater overlap of Rome IV disorders of gut-brain interactions leads to increased disease severity and poorer quality of life. Clin Gastroenterol Hepatol, 2021[online ahead of print]
 
3) Barberio B, Judge C, Savarino EV et al:Global prevalence of functional constipa-tion according to the Rome criteria:a sys-tematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:638-648, 2021
 
4) Mark EB, Klinge MW, Gronlund D et al:Ambulatory assessment of colonic motility using the electromagnetic capsule track-ing system:Effect of opioids. Neurogas-troenterol Motil 32:e13753, 2020
 
5) Shibao CA, Joos K, Phillips JA 3rd et al:Familial autonomic ganglionopathy caused by rare CHRNA3 genetic variants. Neurol-ogy 97:e145-e155, 2021
 
6) Liu J, Lv C, Huang Y et al:Digital rectal examination is a valuable bedside tool for detecting dyssynergic defecation:A di-agnostic study and a meta-analysis. Can J Gastronterol Hepatol 2021:5685610, 2021
 
7) Gwee KA, Gonlachanvit S, Ghoshal UC et al:Second Asian consensus on irritable bowel syndrome. J Neurogastroenterol Motil 25:343-362, 2019
PubMed
8) Fukudo S, Okumura T, Inamori M et al:Evidence-based clinical practice guide-lines for irritable bowel syndrome 2020. J Gastroenterol 56:193-217, 2021
 
9) Ohkubo H, Yoshihara T, Misawa N et al:Relationship between stool form and qual-ity of life in patients with chronic consti-pation:An internet questionnaire survey. Digestion 102:147-154, 2021
 
10) Morishita D, Tomita T, Mori S et al:Senna versus magnesium oxide for the treatment of chronic constipation:A randomized, placebo-controlled trial. Am J Gastroenterol 116:152-161, 2021
PubMed
11) Nakajima A, Shinbo K, Oota A et al:Polyethylene glycol 3350 plus electrolytes for chronic constipation:a 2-week, ran-domized, double-blind, placebo-controlled study with a 52-week open-label extension. J Gastroenterol 54:792-803, 2019
 
12) Kasugai K, Iwai H, Kuboyama N et al:Efficacy and safety of a crystalline lactu-lose preparation(SK-1202)in Japanese patients with chronic constipation:A ran-domized, double-blind, placebo-controlled, dose-finding study. J Gastroenterol 54:530-540, 2019
 
13) Piche T, Dapoigny M:Comparative ef-ficacy and safety of lactulose plus paraf-fin vs polyethylene glycol in functional constipation:a randomised clinical study. United European Gastroenterol J 8:923-932, 2020
 
14) Ohbayashi H, Sato Y, Kiuchi M et al:Open-label study to evaluate the treat-ment continuation rate after a dose re-duction of lubiprostone due to onset of adverse events. Expert Rev Gastroenterol Hepatol 15:333-342, 2021
 
15) Xiao YL, Dai N, He SX et al:Efficacy and safety of lubiprostone for the treatment of functional constipation in Chinese adult patients:A multicenter, randomized, double-blind, placebo-controlled trial. J Dig Dis 22:622-629, 2021
 
16) Rao SSC, Lichtlen P, Habibi S:Effects of lubiprostone, an intestinal secretagogue, on electrolyte homeostasis in chronic idio-pathic and opioid-induced constipation. J Clin Gastroenterol 55:512-519, 2021
 
17) Fukudo S, Hongo M, Kaneko H et al:Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipa-tion. Clin Gastroenterol Hepatol 13:249-301. e5, 2015
 
18) Fukudo S, Miwa H, Nakajima A et al:High-dose linaclotide is effective and safe in patients with chronic constipation:A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan. Neu-rogastroenterol Motil 31:e13487, 2019
 
19) Chang L, Lacy BE, Moshiree B et al:Ef-ficacy of linaclotide in reducing abdominal symptoms of bloating, discomfort, and pain:A phase 3B trial using a novel Ab-dominal Scoring System. Am J Gastroen-terol 116:1929-1937, 2021
 
20) Chey WD, Sayuk GS, Bartolini W et al:Randomized trial of 2 delayed-release for-mulations of linaclotide in patients with ir-ritable bowel syndrome with constipation. Am J Gastroenterol 116:354-361, 2021
 
21) Nakajima A, Seki M, Taniguchi S et al:Safety and efficacy of elobixibat for chronic constipation:results from a ran-domised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepa-tol 3:537-547, 2018
 
22) Misawa N, Higurashi T, Takatsu T et al:The benefit of elobixibat in chronic constipation is associated with faecal de-oxycholic acid but not effects of altered microbiota. Aliment Pharmacol Ther 52:821-828, 2020
 
23) Fukudo S, Nakamura M, Hamatani T et al:Efficacy and safety of 5-HT4 receptor agonist minesapride for irritable bowel syndrome with constipation in a random-ized controlled trial. Clin Gastroenterol Hepatol 19:538-546. e8, 2021
 
24) Hamatani T, Fukudo S, Nakada Y et al:Randomised clinical trial:minesapride vs placebo for irritable bowel syndrome with predominant constipation. Aliment Phar-macol Ther 52:430-441, 2020
 
25) Dimidi E, Zdanaviciene A, Christodou-lides S et al:Randomised clinical trial:Bifidobacterium lactis NCC2818 probioticvs placebo, and impact on gut transit time, symptoms, and gut microbiology in chronic constipation. Aliment Pharmacol Ther 49:251-264, 2019
 
26) Chey WD, Lembo AJ, Yang Y et al:Effi-cacy of tenapanor in treating patients with irritable bowel syndrome with constipa-tion:A 26-week, placebo-controlled phase 3 trial(T3MPO-2). Am J Gastroenterol 116:1294-1303, 2021
 
27) Fukudo S, Endo Y, Hongo M et al:Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation:a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Gastroenterol Hepatol 3:603-613, 2018
PubMed
28) Fukudo S, Kaku K:Effect of mizagliflozin on postprandial plasma glucose in patients with functional constipation. J Neurogas-troenterol Motil 25:332-333, 2019
PubMed
29) Fukudo S, Kaku K:Future possibility of mizagliflozin on functional constipation and/or irritable bowel syndrome with con-stipation. Gastroenterology 157:898-899, 2019
PubMed
30) Crockett SD, Greer KB, Heidelbaugh JJ et al:American Gastroenterological As-sociation Institute Clinical Guidelines Committee:American Gastroenterologi-cal Association Institute Guideline on the medical management of opioid-induced constipation. Gastroenterology 156:218-226, 2019
 
P.125 掲載の参考文献
1) Sung H, Ferlay J, Siegel RL et al:Global cancer statistics 2020:GLOBOCAN esti-mates of incidence and mortality world-wide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021
 
2) Hirasawa T, Aoyama K, Tanimoto T et al:Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic im-ages. Gastric Cancer 21:653-660, 2018
 
3) Ishioka M, Hirasawa T, Tada T:Detect-ing gastric cancer from video images using convolutional neural networks. Dig Endosc 31:e34-e35, 2019
 
4) Ikenoyama Y, Hirasawa T, Ishioka M et al:Detecting early gastric cancer:Com-parison between the diagnostic ability of convolutional neural networks and endos-copists. Dig Endosc 33:141-150, 2021
 
5) Luo H, Xu G, Li C et al:Real-time arti-ficial intelligence for detection of upper gastrointestinal cancer by endoscopy:a multicentre, case-control, diagnostic study. Lancet Oncol 20:1645-1654, 2019
 
6) Takiyama H, Ozawa T, Ishihara S et al:Automatic anatomical classification of esophagogastroduodenoscopy images us-ing deep convolutional neural networks. Sci Rep 8:7497, 2018
 
7) Wu L, He X, Liu M et al:Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary test-ing of its performance in detecting early gastric cancer:a randomized controlled trial. Endoscopy 53:1199-1207, 2021
 
8) Zhu Y, Wang QC, Xu MD et al:Applica-tion of convolutional neural network in the diagnosis of the invasion depth of gastric cancer based on conventional endoscopy. Gastrointest Endosc 89:806-815. e1, 2019
 
9) Yoon HJ, Kim S, Kim JH et al:A lesion-based convolutional neural network im-proves endoscopic detection and depth prediction of early gastric cancer. J Clin Med 8:1310, 2019
 
10) Nagao S, Tsuji Y, Sakaguchi Y et al:Highly accurate artificial intelligence systems to predict the invasion depth of gastric cancer:efficacy of conven-tional white-light imaging, nonmagnifying narrow-band imaging, and indigo-carmine dye contrast imaging. Gastrointest Endosc 92:866-873. e1, 2020
 
11) Shichijo S, Nomura S, Aoyama K et al:Application of convolutional neural net-works in the diagnosis of Helicobacter pylori infection based on endoscopic images. EBioMedicine 25:106-111, 2017
 
12) Shichijo S, Endo Y, Aoyama K et al:Ap-plication of convolutional neural networks for evaluating Helicobacter pylori infection status on the basis of endoscopic images. Scand J Gastroenterol 54:158-163, 2019
 
13) Nakashima H, Kawahira H, Kawachi H et al:Endoscopic three-categorical diagnosis of Helicobacter pylori infection using linkedcolor imaging and deep learning:a single-center prospective study(with video). Gastric Cancer 23:1033-1040, 2020
 
14) Horie Y, Yoshio T, Aoyama K et al:Diag-nostic outcomes of esophageal cancer by artificial intelligence using convolutional neural networks. Gastrointest Endosc 89:25-32, 2019
 
15) Waki K, Ishihara R, Kato Y et al:Useful-ness of an artificial intelligence system for the detection of esophageal squamous cell carcinoma evaluated with videos simulat-ing overlooking situation. Dig Endosc 33:1101-1109, 2021
 
16) Nakagawa K, Ishihara R, Aoyama K et al:Classification for invasion depth of esophageal squamous cell carcinoma us-ing a deep neural network compared with experienced endoscopists. Gastrointest Endosc 90:407-414, 2019
 
17) Shimamoto Y, Ishihara R, Kato Y et al:Real-time assessment of video images for esophageal squamous cell carcinoma inva-sion depth using artificial intelligence. J Gastroenterol 55:1037-1045, 2020
 
18) de Groof AJ, Struyvenberg MR, van der Putten J et al:Deep-learning system de-tects neoplasia in patients with Barrett's esophagus with higher accuracy than endoscopists in a multistep training andvalidation study with benchmarking. Gas-troenterology 158:915-929. e4, 2020
 
19) Ebigbo A, Mendel R, Ruckert T et al:En-doscopic prediction of submucosal invasion in Barrett's cancer with the use of artificial intelligence:a pilot study. Endoscopy 53:878-883, 2021
 
20) Aoki T, Yamada A, Aoyama K et al:Automatic detection of erosions and ulcer-ations in wireless capsule endoscopy im-ages based on a deep convolutional neural network. Gastrointest Endosc 89:357-363. e2, 2019
 
21) Aoki T, Yamada A, Kato Y et al:Auto-matic detection of various abnormalities in capsule endoscopy videos by a deep learning-based system:a multicenter study. Gastrointest Endosc 93:165-173. e1, 2021
 
22) Misawa M, Kudo SE, Mori Y et al:Arti-ficial intelligence-assisted polyp detection for colonoscopy:Initial experience. Gas-troenterology 154:2027-2029. e3, 2018
 
23) Wang P, Berzin TM, Glissen Brown JR et al:Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates:a prospective randomised controlled study. Gut 68:1813-1819, 2019
 
24) Wang P, Liu X, Berzin TM et al:Effect of a deep-learning computer-aided detection system on adenoma detection during colo-noscopy(CADe-DB trial):a double-blind randomised study. Lancet Gastroenterol Hepatol 5:343-351, 2020
 
25) Gong D, Wu L, Zhang J et al:Detection of colorectal adenomas with a real-time com-puter-aided system(ENDOANGEL):a randomised controlled study. Lancet Gas-troenterol Hepatol 5:352-361, 2020
 
26) Yamada A, Niikura R, Otani K et al:Au-tomatic detection of colorectal neoplasia in wireless colon capsule endoscopic images using a deep convolutional neural network. Endoscopy 53:832-836, 2021
 
27) Mori Y, Kudo SE, Wakamura K et al:Novel computer-aided diagnostic system for colorectal lesions by using endocytos-copy(with videos). Gastrointest Endosc 81:621-629, 2015
 
28) Ozawa T, Ishihara S, Fujishiro M et al:Novel computer-assisted diagnosis system for endoscopic disease activity in patients with ulcerative colitis. Gastrointest Endosc 89:416-421. e1, 2019
 
29) Maeda Y, Kudo SE, Mori Y et al:Fully automated diagnostic system with artifi-cial intelligence using endocytoscopy to identify the presence of histologic inflam-mation associated with ulcerative colitis(with video). Gastrointest Endosc 89:408-415, 2019
 
30) Takenaka K, Ohtsuka K, Fujii T et al:Development and validation of a deepneural network for accurate evaluationof endoscopic images from patients withulcerative colitis. Gastroenterology 158:2150-2157, 2020
 
P.132 掲載の参考文献
1) 日本胃癌学会 編:胃癌治療ガイドライン医師用 2021年7月改訂 第6版, 金原出版, 2021
 
2) 日本臨床腫瘍学会, 日本癌治療学会 編:高齢者のがん薬物療法ガイドライン. 南江堂, 2019
 
3) Hall PS, Swinson D, Cairns DA et al:Ef-ficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer:The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol 7:869, 2021
 
4) Cunningham D, Lang I, Marcuello E:AVEX study investigators:Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previouslyuntreated metastatic colorectal cancer(AVEX):an open-label, randomised phase 3 trial. Lancet Oncol 14:1077-1085, 2013
 
5) Winther SB, Liposits G, Skuladottir H et al:Reduced-dose combination chemother-apy(S-1 plus oxaliplatin)versus full-dose monotherapy(S-1)in older vulnerable patients with metastatic colorectal cancer(NORDIC9):a randomised, open-labelphase 2 trial. Lancet Gastroenterol Hepa-tol 4:376-388, 2019
 
6) Mohile SG, Dale W, Somerfield MR et al:Practical assessment and management of vulnerabilities in older patients receiving chemotherapy:ASCO Guideline for Ge-riatric Oncology. J Clin Oncol 36:2326-2347, 2018
 
7) Li D, Sun CL, Kim H et al:Geriatric As-sessment-Driven Intervention(GAIN) on chemotherapy-related toxic effects in olderadults with cancer:A randomized clinical trial. JAMA Oncol 7:e214158, 2021
 
8) 国立がん研究センター:がん情報サービス-がん統計 https://ganjoho.jp/reg_stat/index.html
 
9) Bando H, Yamada Y, Tanabe S et al:Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Can-cer 19:919-926, 2016
 
10) Seymour MT, Thompson LC, Wasan HS et al:FOCUS2 Investigators;National Can-cer Research Institute Colorectal Cancer Clinical Studies Group:Chemotherapy options in elderly and frail patients with metastatic colorectal cancer(MRC FO-CUS2):an open-label, randomised factorial trial. Lancet 377(9779):1749-1759, 2011
 
11) Ohta T, Kato T, Kawakami H et al:Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naive older or frail patients with metastatic colorectal cancer(OGSG 0802). Int J Clin Oncol 25:1291-1298, 2020
PubMed
12) 大腸癌研究会 編:大腸癌治療ガイドライン 医師用 2019年版. 金原出版, 2019
 
13) Aparicio T, Darut-Jouve A, Khemissa Akouz F et al:Single-arm phase II trial to evaluate efficacy and tolerance of rego-rafenib monotherapy in patients over 70 with previously treated metastatic colorec-tal adenocarcinoma FFCD 1404-REGOLD. J Geriatr Oncol 11:1255-1262, 2020
 
14) Carrato A, Benavides M, Massuti B et al:First-line single-agent regorafenib in frail patients with metastatic colorectal can-cer:a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours(TTD). BMC Cancer 19:533, 2019
 
15) Petrioli R, Chirra M, Messuti L et al:Efficacy and safety of regorafenib with 2/1 schedule for patients >- 75 years with Metastatic Colorectal Cancer(mCRC)af-ter failure of 2 lines of chemotherapy. Clin Colorectal Cancer 17:307-312, 2018
 
16) Van Cutsem E, Danielewicz I, Saunders MP et al:Trifluridine/tipiracil plus beva-cizumab in patients with untreated meta-static colorectal cancer ineligible for inten-sive therapy:the randomized TASCO1 study. Ann Oncol 31:1160-1168, 2020
 
17) Oki E, Makiyama A, Miyamoto Y et al:Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly pa-tients with metastatic colorectal cancer(KSCC1602):A multicenter phase II trial. Cancer Med 10:454-461, 2021
 
18) Andre T, Saunders M, Kanehisa A et al:First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer:SOLSTICE study de-sign. Future Oncol 16:21-29, 2020
 
19) Marmorino F, Rossini D, Lonardi S et al:Impact of age and gender on the safety and efficacy of chemotherapy plus beva-cizumab in metastatic colorectal cancer:a pooled analysis of TRIBE and TRIBE2 studies. Ann Oncol 30:1969-1977, 2019
 
20) Janjigian YY, Shitara K, Moehler M et al:First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma(CheckMate 649):a randomised, open-label, phase 3 trial. Lancet 398(10294):27-40, 2021
PubMed
21) Boku N, Ryu MH, Oh DY et al:LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with pre-viously untreated advanced or recurrent gastric/gastroesophageal junction(G/GEJ)cancer:ATTRACTION-4(ONO-4538-37)study. Ann Oncol 31:S1192, 2020
 
22) Sun JM, Shen L, Shah MA et al:KEY-NOTE-590 Investigators:Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):a randomised, placebo-controlled, phase 3 study. Lancet 398(10302):759-771, 2021
 
23) Presley CJ, Gomes F, Burd CE et al:Im-munotherapy in older adults with cancer. J Clin Oncol 39(19):2115-2127, 2021
 
24) Landre T, Des Guetz G, Chouahnia K et al:Immune checkpoint inhibitors for patients aged >-75 years with advanced cancer in first- and second-line settings:A meta-analysis. Drugs Aging 37:747-754, 2020
PubMed
P.139 掲載の参考文献
1) Ito T, Masui T, Komoto I et al:JNETS clinical practice guidelines for gastroenter-opancreatic neuroendocrine neoplasms:diagnosis, treatment, and follow-up:a synopsis. J Gastroenterol 56:1033-1044, 2021
 
2) Das S, Dasari A:Epidemiology, incidence, and prevalence of neuroendocrine neo-plasms:Are there global differences? Curr Oncol Rep 23:43, 2021
 
3) Masui T, Ito T, Uemoto S:JNETS Proj-ect Study Group:Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms(GEP-NEN)in Japan:a population-based study. BMC Cancer 20:1104, 2020
 
4) Sorbye H, Baudin E, Borbath I et al:Un-met needs in high-grade gastroenteropan-creatic neuroendocrine neoplasms(WHO G3). Neuroendocrinology 108:54-62, 2019
 
5)Park HY, Kwon MJ, Kang HS et al:Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets. Hum Pathol 87:83-94, 2019
PubMed
6) Perez K, Kulke MH, Chittenden A et al:Clinical implications of pathogenic germ-line variants in Small Intestine Neuroen-docrine Tumors(SI-NETs). JCO Precis Oncol 5:808-816, 2021
 
7) Sharma R, Lythgoe MP, Patel N:Explor-ing the epigenome in gastroenteropancre-atic neuroendocrine neoplasias. Cancers 13:4181, 2021
 
8) De Mestier L, Couvelard A, Blazevic A et al:Critical appraisal of MGMT in diges-tive NET treated with alkylating agents. Endocr Relat Cancer 27:R391-R405, 2020
 
9) Hane Y, Tsuchikawa T, Tanaka K et al:Metachronous liver metastases after long-term follow-up of endoscopic resection for rectal neuroendocrine neoplasms:a report of three cases. Surg Case Rep 6:22, 2020
PubMed
10) Kang HS, Kwon MJ, Kim TH et al:Lym-phovascular invasion as a prognostic value in small rectal neuroendocrine tumor treated by local excision:A systematic review and meta-analysis. Pathol Res Pract 215:152642, 2019
 
11) Chatzellis E, Angelousi A, Daskalakis K et al:Activity and safety of standard and prolonged capecitabine/temozolomide administration in patients with advanced neuroendocrine neoplasms. Neuroendocri-nology 109:333-345, 2019
 
12) Thomas K, Voros BA, Meadows-Taylor M et al:Outcomes of capecitabine and temozolomide(CAPTEM)in advanced neuroendocrine neoplasms(NENs). Can-cers(Basel) 12:206, 2020
 
13) Xu J, Shen L, Bai C et al:Surufatinib in advanced pancreatic neuroendocrine tumours(SANET-p):a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:1489-1499, 2020
 
14) Xu J, Shen L, Zhou Z et al:Surufatinib in advanced extrapancreatic neuroendocrine tumours(SANET-ep):a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21:1500-1512, 2020
PubMed
15) Kobayashi N, Wild D, Kaul F et al:Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepatobiliary Pancreat Sci 28:727-739, 2021
PubMed
16) Liu AJ, Ueberroth BE, McGarrah PW et al:Treatment outcomes of well-differen-tiated high-grade neuroendocrine tumors. Oncologist 26:383-388, 2021
 
17) Apostolidis L, Dal Buono A, Merola E et al:Multicenter analysis of treatment out-comes for systemic therapy in well differ-entiated grade 3 neuroendocrine tumors(NET G3). Cancers(Basel) 13:1936, 2021
 
18) Sorbye H, Kong G, Grozinsky-Glasberg S:PRRT in high-grade gastroenteropan-creatic neuroendocrine neoplasms(WHO G3). Endocr Relat Cancer 27:R67-R77, 2020
 
19) Albertelli M, Dotto A, Nista F et al:"Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 22:615-636, 2021
PubMed
20) Hasic Telalovic J, Pillozzi S, Fabbri R et al:A machine learning decision support system(DSS)for neuroendocrine tumor patients treated with somatostatin analog(ssa)therapy. Diagnostics(Basel) 11:804, 2021
PubMed
21) Leyden S, Kolarova T, Bouvier C et al:Unmet needs in the international neuro-endocrine tumor(NET)community:Assessment of major gaps from the per-spective of patients, patient advocates and NET health care professionals. Int J Cancer 146:1316-1323, 2020
 

II章 肝

P.149 掲載の参考文献
1) Wedemeyer H, Schoneweis K, Bogomolov PO et al:48 weeks of high dose(10mg) bulevirtide as monotherapy or with pegin-terferon alfa-2a in patients with chronic HBV/HDV co-infection. J Hepatol 73:S52-S53, 2020
 
2) Yuen MF, Wong DK, Schluep T et al:Long-term serological, virological and his-tological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut, 2021[online ahead of print]
 
3) Yuen MF, Heo J, Jang JW et al:Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B:a phase 2 randomized controlled trial. Nat Med 27:1725-1734, 2021
PubMed
4) Han K, Cremer J, Elston R et al:A ran-domized, double-blind, placebo-controlled, first-time-in-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects. Clin Pharmacol Drug Dev 8:790-801, 2019
 
5) Yuen MF, Agarwal K, Gane EJ et al:Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor:A randomised, placebo-controlled phase 1 trial. Lancet Gastroen-terol Hepatol 5:152-166, 2020
 
6) Yuen MF, Gane EJ, Kim DJ et al:Antivi-ral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology 156:1392-1403. e7, 2019
 
7) Boulon R, Blanchet M, Lemasson M et al:Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro. Antivir Res 183:104853, 2020
PubMed
8) Vaillant A:REP 2139:Antiviral mecha-nisms and applications in achieving func-tional control of HBV and HDV infection. ACS Infect Dis 5:675-687, 2019
 
9) Bazinet M, Pantea V, Placinta G et al:Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pe-gylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy. Gastroenterology 158:2180-2194, 2020
PubMed
10) Maini MK, Burton AR:Restoring, releas-ing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol 16:662-675, 2019
PubMed
11) Pauken KE, Sammons MA, Odorizzi PM et al:Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354:1160-1165, 2016
PubMed
12) Lok AS, Pan CQ, Han SH et al:Ran-domized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepa-tol 65:509-516, 2016
 
13) Fazle Akbar SM, Mahtab MA, Aguilar JC et al:Sustained antiviral and liver protection by a nasal therapeutic vaccine(NASVAC, containing both HBsAg and HBcAg)in patients with chronic hepatitis B:2-year follow-up of phase III clinical trial. Pathogens 10:1440, 2021
 
14) Zoulim F, Fournier C, Habersetzer F et al:Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients:A phase 1b placebo-controlled trial. Hum Vaccin Immunother 16:388-399, 2020
PubMed
15) Vir Biotechnology Inc:Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Dem-onstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen. (January 26, 2021)
 
16) Gane EJ, Kim HJ, Visvanathan K et al:Safety, pharmacokinetics, and pharmaco-dynamics of the oral TLR8 agonist selgan-tolimod in chronic hepatitis B. Hepatology 74:1737-1749, 2021
 
17) Gane E, Verdon DJ, Brooks AE et al:Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B:A pilot study. J Hepatol 71:900-907, 2019
PubMed
18) Fergusson JR, Wallace Z, Connolly MM et al:Immune-mobilizing monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells. Hepatology 72:1528-1540, 2020
PubMed
19) Damato BE, Dukes J, Goodall H et al:Tebentafusp:T cell redirection for the treatment of metastatic uveal melanoma. Cancers(Basel) 11:971, 2019
PubMed
20) Mouzannar K, Fusil F, Lacombe B et al:Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo. FASEB J 33:2472-2483, 2019
 
21) Erken R, Stelma F, Roy E et al:First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001. J Hepatol 68:S488-S489, 2018
 
22) Michler T, Kosinska AD, Festag J et al:Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology 158:1762-1775, 2020
PubMed
23) Dusheiko G:Will we need novel combina-tions to cure HBV infection? Liver Int 40(Suppl 1):35-42, 2020
 
24) Inoue T, Kusumoto S, Iio E et al:Clinical efficacy of a novel, high-sensitivity HB-crAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepa-tol 75:302-310, 2021
 
P.155 掲載の参考文献
1) Cheng X, Uchida T, Xia Y et al:Dimin-ished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest 130:3205-3220, 2020
 
2) Zhang Z, Trippler M, Real CI et al:Hepatitis B virus particles activate toll-like receptor 2 signaling initially upon infection of primary human hepatocytes. Hepatol-ogy 72:829-844, 2020
 
3) Wang YX, Niklasch M, Liu T et al:Interferon-inducible MX2 is a host restric-tion factor of hepatitis B virus replication. J Hepatol 72:865-876, 2020
 
4) Kawashima K, Isogawa M, Onishi M et al:Restoration of type I interferon signal-ing in intrahepatically primed CD8+T cells promotes functional differentiation. JCI Insight 6:e145761, 2021
PubMed
5) Kuipery A, Sanchez Vasquez JD, Mehro-tra A et al:Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T cell recognition of infected HepG2-NTCP. Hepatology, 2021[online ahead of print]
 
6) Riedl T, Faure-Dupuy S, Rolland M et al:Hypoxia-inducible factor 1 alpha-mediated RelB/APOBEC3B down-regulation allows hepatitis B virus persistence. Hepatology 74:1766-1781, 2021
PubMed
7) Nishio A, Bolte FJ, Takeda K et al:Clear-ance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection. Sci Transl Med 13(587):eaba6322, 2021
 
8) Chen J, Li Y, Lai F et al:Functional com-parison of interferon-α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-α and in-terferon-γ signaling. Hepatology 73:486-502, 2021
 
9) De Pasquale C, Campana S, Barberi C et al:Human hepatitis B virus negatively impacts the protective immune crosstalk between natural killer and dendritic cells. Hepatology 74:550-565, 2021
PubMed
10) Wijaya RS, Read SA, Truong NR et al:HBV vaccination and HBV infection induc-es HBV-specific natural killer cell memory. Gut 70:357-369, 2021
 
11) De Simone G, Andreata F, Bleriot C et al:Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. Immu-nity 54:2089-2100. e8, 2021
 
12) Garcia-Lopez M, Lens S, Pallett LJ et al:Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B pa-tients. J Hepatol 74:1064-1074, 2021
 
13) Li Y, Tang L, Guo L et al:CXCL13-medi-ated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection. J Hepatol 72:420-430, 2020
 
14) Heim K, Binder B, Sagar et al:TOX de-fines the degree of CD8+T cell dysfunction in distinct phases of chronic HBV infection. Gut 70:1550-1560, 2020
 
15) Le Bert N, Gill US, Hong M et al:Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection. Gastro-enterology 159:652-664, 2020
 
16) Aliabadi E, Urbanek-Quaing M, Maasoumy B et al:Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut, 2021[on-line ahead of print]
 
17) Fumagalli V, Di Lucia P, Venzin V et al:Serum HBsAg clearance has minimal im-pact on CD8+T cell responses in mouse models of HBV infection. J Exp Med 217:e20200298, 2020
PubMed
18) Michler T, Kosinska AD, Festag J et al:Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology 158:1762-1775. e9, 2020
 
19) Benechet AP, De Simone G, Di Lucia P et al:Dynamics and genomic landscape of CD8+T cells undergoing hepatic priming. Nature 574(7777):200-205, 2019
PubMed
20) Acerbi G, Montali I, Ferrigno GD et al:Functional reconstitution of HBV-specific CD8+T cells by in vitro polyphenol treat-ment in chronic hepatitis B. J Hepatol 74:783-793, 2021
 
21) Ma H, Lim TH, Leerapun A et al:Thera-peutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP Rep 3:100361, 2021
 
22) Fergusson JR, Wallace Z, Connolly MM et al:Immune-mobilizing monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells. Hepatology 72:1528-1540, 2020
PubMed
23) Wang H, Luo H, Wan X et al:TNF-α/IFN-γ profile of HBV-specific CD4+T cells is associated with liver damage and viral clearance in chronic HBV infection. J Hepatol 72:45-56, 2020
 
24) Yoshikawa S, Yoshio S, Yoshida Y et al:Impact of immune reconstitution-induced hepatic flare on hepatitis B surface antigen loss in hepatitis B virus/human immuno-deficiency virus-1 coinfected patients. J Infect Dis 223:2080-2089, 2021
 
25) Graves AM, Virdis F, Morrison E et al:Human hepatitis B viral infection out-comes are linked to naturally occurring variants of HLA-DOA that have altered function. J Immunol 205:923-935, 2020
 
26) Le Bert N, Salimzadeh L, Gill US et al:Comparative characterization of B cells specific for HBV nucleocapsid and en-velope proteins in patients with chronic hepatitis B. J Hepatol 72:34-44, 2020
 
27) Vanwolleghem T, Groothuismink ZMA, Kreefft K et al:Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chron-ic HBV. J Hepatol 73:52-61, 2020
 
28) Xu H, Locarnini S, Wong D et al:Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol 76:34-45, 2021
 
29) Tsai TY, Huang MT, Sung PS et al:SIGLEC-3(CD33)serves as an immune checkpoint receptor for HBV infection. J Clin Invest 131:e141965, 2021
PubMed
30) Amin OE, Colbeck EJ, Daffis S et al:Therapeutic potential of TLR8 agonist GS-9688(Selgantolimod)in chronic hepatitis B:Remodeling of antiviral and regulatory mediators. Hepatology 74:55-71, 2021
PubMed
P.162 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会 編:C型肝炎治療ガイドライン(第8版). 2020
 
2) Tahata Y, Hikita H, Mochida S et al:Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decom-pensated cirrhosis:a Japanese real-world multicenter study. J Gastroenterol 56:67-77, 2021
 
3) Daniel KE, Saeian K, Rizvi S et al:Real-world experiences with direct-acting anti-viral agents for chronic hepatitis C treat-ment. J Viral Hepat 27:195-204, 2020
 
4) Iwamoto T, Saeki I, Hidaka I et al:Novel therapeutic strategy using interventional radiology(IVR)for hepatitis C virus(HCV)-related decompensated liver cir-rhosis:A case report. Am J Case Rep 20:1699-1704, 2019
 
5) Janjua NZ, Wong S, Abdia Y et al:Impact of direct-acting antivirals for HCV on mor-tality in a large population-based cohort study. J Hepatol 75:1049-1057, 2021
 
6) Torgersen J, Newcomb CW, Carbonari DM et al:Protease inhibitor-based direct-act-ing antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J Hepatol 75:1312-1322, 2021
PubMed
7) Liu CH, Yang SS, Peng CY et al:Gle-caprevir/pibrentasvir for patients with chronic hepatitis C virus infection and se-vere renal impairment. J Viral Hepat 27:568-575, 2020
 
8) Yen HH, Su PY, Zeng YH et al:Glecapre-vir-pibrentasvir for chronic hepatitis C:Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS One 13:15:e0237582, 2020
 
9) Taneja S, Duseja A, Mehta M et al:Sofos-buvir and velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on mainte-nance haemodialysis. Liver Int 41:705-709, 2021
 
10) Tronina O, Durlik M, Orlowska I et al:Real-world direct-acting antiviral treat-ment in kidney transplant and hemodi-alysis patients:the EpiTer-2 multicenter observational study. Ann Gastroenterol 34:438-446, 2021
 
11) Midorikawa Y, Takayama T, Nakayama H et al:Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma. BMC Gastroenterol 19:147, 2019
 
12) Poola S, Sanaka S, Sewell K et al:Hepati-tis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C. J Viral Hepat 28:373-382, 2021
 
13) Mawatari S, Oda K, Kumagai K et al:Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. Hepatol Res 50:453-465, 2020
PubMed
14) Takaki S, Imamura M, Yamaguchi S et al:Real-word efficacy of sofosbuvir, vel-patasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clin J Gastroenterol 13:1233-1238, 2020
PubMed
15) Dietz J, Spengler U, Mullhaupt B et al:Efficacy of retreatment after failed direct-acting antiviral therapy in patients with HCV genotype 1-3 infections. Clin Gastro-enterol Hepatol 19:195-198, 2021
 
16) Yamashita T, Takeda H, Takai A et al:Single-molecular real-time deep sequenc-ing reveals the dynamics of multi-drug resistant haplotypes and structural varia-tions in the hepatitis C virus genome. Sci Rep 10:2651, 2020
 
17) Chang KC, Tung SY, Wei KL et al:Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci Rep 11:13543, 2021
PubMed
18) Tada T, Nishimura T, Matono T et al:Association of liver stiffness and steatosis with hepatocellular carcinoma develop-ment in patients with hepatitis C virus infection who received direct-acting an-tiviral therapy and achieved sustained virological response. Hepatol Res 51:860-869, 2021
 
19) Toyoda H, Yasuda S, Shiota S et al:Pre-treatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. Aliment Phar-macol Ther 53:1309-1316, 2021
 
20) Yuri Y, Nishikawa H, Enomoto H et al:Impact of sustained virological response for gastroesophageal varices in hepatitis-C-virus-related liver cirrhosis. J Clin Med 9:95, 2019
PubMed
21) Semmler G, Binter T, Kozbial K et al:Noninvasive risk stratification after HCV eradication in patients with advanced chronic liver disease. Hepatology 73:1275-1289, 2021
PubMed
22) D'Ambrosio R, Degasperi E, Anolli MP et al:Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol, 2021[online ahead of print]
 
23) European Association for the Study of the Liver:EASL recommendations on treat-ment of hepatitis C:Final update of the series. EASL J Hepatol 73:1170-1218, 2020
 
24) Toyoda H, Atsukawa M, Watanabe T et al:Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting:A large, multicenterstudy from Japan. J Gastroenterol Hepatol 35:1420-1425, 2020
 
25) Ichikawa S, Motosugi U, Ichikawa T et al:Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci 11:291-297, 2012
PubMed
26) Higuchi M, Tamaki N, Kurosaki M et al:Changes of liver stiffness measured by magnetic resonance elastography dur-ing direct-acting antivirals treatment in patients with chronic hepatitis C. J Med Virol 93:3744-3751, 2021
 
27) Chen JY, Cheng PN, Chiu YC et al:Persistent augmentation of central arte-rial stiffness following viral clearance by direct-acting antivirals in chronic hepatitis C. J Viral Hepat 28:159-167, 2021
 
28) Su X, Zhao X, Deng JL et al:Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes:A systematic review and meta-analysis. J Viral Hepat 28:664-671, 2021
PubMed
29) Su PY, Su WW, Wu LS et al:Reduction of shear wave elastography but not shear wave dispersion after successful hepatitis C treatment with direct-acting antiviral agents. J Ultrasound Med 40:1919-1926, 2021
 
30) Yeung A, Palmateer NE, Dillon JF et al:Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol, 2021[online ahead of print]
 
P.168 掲載の参考文献
1) Tahata Y, Hikita H, Mochida S et al:Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decom-pensated cirrhosis:a Japanese real-world multicenter study. J Gastroenterol 56:67-77, 2021
 
2) Takaoka Y, Miura K, Morimoto N et al:Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for pa-tients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res 51:51-61, 2021
 
3) Atsukawa M, Tsubota A, Kondo C et al:Real-world clinical application of 12-week sofosbuvir/velpatasvir treatment for de-compensated cirrhotic patients with geno-type 1 and 2:A prospective, multicenter study. Infect Dis Ther 9:851-866, 2020
 
4) Tada T, Kurosaki M, Nakamura S et al:Real-world clinical outcomes of sofosbu-vir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis:A nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol 93:6247-6256, 2021
 
5) Ohya K, Imamura M, Teraoka Y et al:Re-al-world efficacy of sofosbuvir plus velpa-tasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res 50:1234-1243, 2020
 
6) Sakamori R, Yamada R, Shinkai K et al:Improvement of skeletal muscle mass af-ter ledipasvir and sofosbuvir treatment for hepatitis C virus in decompensated liver cirrhosis. Intern Med 60:745-750, 2021
 
7) El-Sherif O, Jiang ZG, Tapper EB et al:Baseline factors associated with improve-ments in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology 154:2111-2121. e8, 2018
 
8) Debnath P, Chandnani S, Rathi P et al:A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus. Clin Exp Hepatol 6:253-262, 2020
PubMed
9) Gentile I, Scotto R, Coppola C et al:Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrho-sis:results from an Italian real-life cohort(Liver Network Activity-LINA cohort). Hepatol Int 13:66-74, 2019
 
10) Berkan-Kawinska A, Piekarska A, Jancze-wska E et al:Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic de-compensation:Epi-Ter2 Study. Liver Int 41:1789-1801, 2021
 
11) Cachay ER, Mena A, Morano L et al:Hepatitis C treatment outcomes in persons with HIV and decompensated cirrhosis us-ing a collaborative multidisciplinary HIV-centered approach. J Int Assoc Provid AIDS Care 20:23259582211024771, 2021
 
12) Quaranta MG, Ferrigno L, Tata X et al:Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis:data from the PITER cohort. BMC Infect Dis 21:413, 2021
PubMed
13) Mecci AJ, Kemos P, Leen C et al:The as-sociation between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Ali-ment Pharmacol Ther 50:204-214, 2021
 
14) Verna EC, Morelli G, Terrault NA et al:DAA therapy and long-term hepatic function in advanced/decompensated cir-rhosis:Real-world experience from HCV-TARGET cohort. J Hepatol 73:540-548, 2020
 
15) Krassenburg LAP, Maan R, Ramji A et al:Clinical outcomes following DAA ther-apy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol 74:1053-1063, 2021
 
16) Knop V, Hoppe D, Vermehren J et al:Non-invasive assessment of fibrosis regres-sion and portal hypertension in patients with advanced chronic hepatitis C virus(HCV)-associated liver disease and sus-tained virologic response(SVR):3 years follow-up of a prospective longitudinal study. J Viral Hepat 28:1604-1613, 2021
 
17) Diez C, Berenguer J, Ibanez-Samaniego L et al:Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis. Clin Infect Dis 71:2726-2729, 2020
PubMed
18) Mandorfer M, Kozbial K, Schwabl P et al:Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained viro-logic response to interferon-free therapy. Hepatology 71:1023-1036, 2020
 
19) Lens S, Baiges A, Alvarado-Tapias E et al:Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol 73:1415-1424, 2020
PubMed
20) Kilany S, Ata L, Gomaa A et al:De-creased incidence of hepatocellular carcinoma after directly acting antiviral therapy in patients with hepatitis C-related advanced fibrosis and cirrhosis. J Hepatocell Carcinoma 8:925-935, 2021
 
21) Lusivika-Nzinga C, Fontaine H, Dorival C et al:The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. J Viral Hepat 26:1489-1492, 2019
PubMed
22) Sandmann L, Dorge P, Wranke A et al:Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation:real-life data from five German transplant centers. Eur J Gastro-enterol Hepatol 31:1049-1056, 2019
 
23) Peters MG, Kottilil S, Terrault N et al:Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. Am J Transplant 21:1780-1788, 2021
PubMed
24) Bittermann T, Reddy KR:In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent. Clin Gas-troenterol Hepatol 19:2389-2397. e2, 2021
 
25) European Association for the Study of the Liver:EASL recommendations on treat-ment of hepatitis C:Final update of the series. J Hepatol 73:1170-1218, 2020
 
26) Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel:Hepatitis C Guidance 2019 Update:American As-sociation for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 71:686-721, 2020
 
27) McDonald SA, Barclay ST, Innes HA et al:Uptake of interferon-free DAA therapy among HCV-infected decompen-sated cirrhosis patients and evidence for decreased mortality. J Viral Hepat 28:1246-1255, 2021
 
28) Kumada T, Toyoda H, Yasuda S et al:Comparison of the prognosis of decompen-sated cirrhosis in patients with and with-out eradication of hepatitis C virus. Infect Dis Ther 10:1001-1013, 2021
 
29) Maesaka K, Sakamori R, Yamada R et al:Clinical course of hepatitis C virus-positive patients with decompensated liver cir-rhosis in the era of direct-acting antiviral treatment. Hepatol Res 51:517-527, 2021
 
30) Fujiyama S, Akuta N, Sezaki H et al:Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis:a ret-rospective long-term cohort study. BMC Gastroenterol 21:189, 2021
 
P.175 掲載の参考文献
1) European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of alcohol-related liver dis-ease. J Hepatol 69:154-181, 2018
 
2) Crabb DW, Im GY, Szabo G et al:Diagnosis and treatment of alcohol-associated liver diseases:2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 71:306-333, 2020
 
3) European Association for the Study of the Liver(EASL), European Association for the Study of Diabetes(EASD), Euro-pean Association for the Study of Obesity(EASO):EASL-EASD-EASO Clinical Prac-tice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388-1402, 2016
 
4) Chalasani N, Younossi Z, Lavine JE et al:The diagnosis and management of nonal-coholic fatty liver disease:practical guid-ance from the American Association for the Study of Liver Diseases. Hepatology 67:328-357, 2018
 
5) 日本消化器病学会・日本肝臓学会 編:NAFLD/NASH診療ガイドライン 2020(改訂第2版). 南江堂, 2020
 
6) Tokushige K, Ikejima K, Ono M et al:Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/non-alcoholic steatohepatitis 2020. J Gastroen-terol 56:951-963, 2021
 
7) Eslam M, Newsome PN, Sarin SK et al:A new definition for metabolic dysfunction-associated fatty liver disease:an inter-national expert consensus statement. J Hepatol 73:202-209, 2020
 
8) World Health Organization:International Classification of Diseases 11th Revision. The global standard for diagnostic health information. Geneva:World Health Orga-nization, 2022
 
9) Tian C, Stokowski RP, Kershenobich D et al:Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42:21-23, 2010
PubMed
10) Buch S, Stickel F, Trepo E et al:A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cir-rhosis. Nat Genet 47:1443-1448, 2015
 
11) Schwantes-An TH, Darlay R, Mathurin P et al:Genome-wide association study and meta-analysis on alcohol-associated liver cirrhosis identifies genetic risk factors. Hepatology 73:1920-1931, 2021
PubMed
12) Satishchandran A, Ambade A, Rao S, et al:MicroRNA 122, regulated by GRLH2, protects livers of mice and patients from ethanol-induced liver disease. Gastroenter-ology 154:238-252. e7, 2018
 
13) Ambade A, Satishchandran A, Szabo G:Alcoholic hepatitis accelerates early hepa-tobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 6:20340, 2016
 
14) Tripathi A, Debelius J, Brenner DA et al:The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroen-terol Hepatol 15:397-411, 2018
 
15) Smirnova E, Puri P, Muthiah MD et al:Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity.Hepatology 72:271-286, 2020
 
16) Yang AM, Inamine T, Hochrath K et al:Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest 127:2829-2841, 2017
PubMed
17) Jiang L, Lang S, Duan Y et al:Intestinal virome in patients with alcoholic hepatitis. Hepatology 72:2182-2196, 2020
PubMed
18) Duan Y, Llorente C, Lang S, et al:Bac-teriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575:505-511, 2019
 
P.181 掲載の参考文献
1) Paik JM, Golabi P, Younossi Y et al:Changes in the global burden of chronic liver diseases from 2012 to 2017:The growing impact of NAFLD. Hepatology 72:1605-1616, 2020
PubMed
2) Li J, Zou B, Yeo YH et al:Prevalence, in-cidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019:a sys-tematic review and meta-analysis. Lancet Gastroenterol Hepatol 4:389-398, 2019
 
3) Ito T, Ishigami M, Zou B et al:The epi-demiology of NAFLD and lean NAFLD in Japan:a meta-analysis with individual and forecasting analysis, 1995-2040. Hepa-tol Int 15:366-379, 2021
 
4) Ye Q, Zou BY, Yeo YH et al:Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease:a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 5:739-752, 2020
PubMed
5) Yamada G, Hagiwara Y, Kimura T et al:Impact of body weight gain on the inci-dence of nonalcoholic fatty liver disease in nonobese Japanese individuals. Am J Gastroenterol 116:733-740, 2021
 
6) Younossi ZM, Golabi P, de Avila L et al:The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:A systematic review and meta-analysis. J Hepatol 71:793-801, 2019
PubMed
7) Tateishi R, Matsumura T, Okanoue T et al:Hepatocellular carcinoma develop-ment in diabetic patients:a nationwide survey in Japan. J Gastroenterol 56:261-273, 2021
 
8) Anstee QM, Darlay R, Cockell S et al:Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol 73:505-515, 2020
 
9) Teo K, Abeysekera KWM, Adams L et al:rs641738C > T near MBOAT7 is as-sociated with liver fat, ALT and fibrosis in NAFLD:A meta-analysis. J Hepatol 74:20-30, 2021
 
10) Taylor RS, Taylor RJ, Bayliss S et al:Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease:A systematic review and meta-analysis. Gastroenterology 158:1611-1625. e12, 2020
 
11) Sanyal AJ, Van Natta ML, Clark J et al:Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 385:1559-1569, 2021
PubMed
12) Simon TG, Roelstraete B, Khalili H et al:Mortality in biopsy-confirmed nonalcoholic fatty liver disease:results from a nation-wide cohort. Gut 70:1375-1382, 2021
 
13) Simon TG, Roelstraete B, Hagstrom H et al:Non-alcoholic fatty liver disease and incident major adverse cardiovascular events:results from a nationwide histol-ogy cohort. Gut, 2021[online ahead of print]
 
14) Allen AM, Hicks SB, Mara KC et al:The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol 71:1229-1236, 2019
PubMed
15) Kleiner DE, Brunt EM, Wilson LA et al:Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open 2:e1912565, 2019
PubMed
16) Brunt EM, Kleiner DE, Carpenter DH et al:NAFLD:Reporting histologic find-ings in clinical practice. Hepatology 73:2028-2038, 2021
 
17) Liu F, Goh GB, Tiniakos D et al:qFIBS:An automated technique for quantitative evaluation of fibrosis, inflammation, bal-looning, and steatosis in patients with non-alcoholic steatohepatitis. Hepatology 71:1953-1966, 2020
 
18) Forlano R, Mullish BH, Giannakeas N et al:High-throughput, machine learning-based quantification of steatosis, inflam-mation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 18:2081-2090. e9, 2020
 
19) Taylor-Weiner A, Pokkalla H, Han L et al:A machine learning approach enables quantitative measurement of liver histol-ogy and disease monitoring in NASH. Hepatology 74:133-147, 2021
 
20) Younes R, Caviglia GP, Govaere O et al:Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. J Hepatol 75:786-794, 2021
PubMed
21) Ishiba H, Sumida Y, Seko Y et al:Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with Type 2 Diabetes. Hepatol Commun 5:559-572, 2021
PubMed
22) Newsome PN, Sasso M, Deeks JJ et al:FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with signifi-cant activity and fibrosis:a prospective derivation and global validation study. Lan-cet Gastroenterol Hepatol 5:362-373, 2020
 
23) Sugimoto K, Lee DH, Lee JY et al:Multi-parametric US for identifying patients with high-risk NASH:A derivation and valida-tion study. Radiology 301:625-634, 2021
 
24) Petta S, Sebastiani G, Vigano M et al:Monitoring occurrence of liver-related events and survival by transient elastog-raphy in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol 19:806-815. e5, 2021
 
25) Anstee QM, Lawitz EJ, Alkhouri N et al:Noninvasive tests accurately identify advanced fibrosis due to NASH:Baseline data from the STELLAR trials. Hepatol-ogy 70:1521-1530, 2019
 
26) Tamaki N, Munaganuru N, Jung J et al:Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regres-sion in non-alcoholic fatty liver disease. Gut, 2021 [online ahead of print]
 
27) Eslam M, Newsome PN, Sarin SK et al:A new definition for metabolic dysfunction-associated fatty liver disease:An inter-national expert consensus statement. J Hepatol 73:202-209, 2020
 
28) Lin S, Huang J, Wang M et al:Compari-son of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 40:2082-2089, 2020
 
29) van Kleef LA, Ayada I, Alferink L et al:Metabolic dysfunction associated fatty liv-er disease improves detection of high liver stiffness:The Rotterdam Study. Hepatol-ogy, 2021[online ahead of print]
 
P.188 掲載の参考文献
1) Younossi ZM, Corey KE, Lim JK:AGA clinical practice update on lifestyle modi-fication using diet and exercise to achieve weight loss in the management of nonal-coholic fatty liver disease:Expert review. Gastroenterology 160:912-918, 2021
 
2) 日本消化器病学会, 日本肝臓学会 編:NAFLD/NASH診療ガイドライン 2020(改訂第2版). 南江堂, 2020
 
3) Pafili K, Roden M:Nonalcoholic fatty liver disease(NAFLD)from pathogenesis to treatment concepts in human. Mol Me-tabol 50:101122, 2021
 
4) Lassailly G, Caiazzo R, Ntandja-Wandji LC et al:Bariatric surgery provides long-term resolution of nonalcoholic steatohepa-titis and regression of fibrosis. Gastroen-terology 159:1290-1301. e5, 2020
 
5) Takahashi H, Kessoku T, Kawanaka M et al:Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun, 2021[online ahead of print]
 
6) Newsome PN, Buchholtz K, Cusi K et al:A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepati-tis. N Engl J Med 384:1113-1124, 2021
 
7) Harrison SA, Alkhouri N, Davison BA et al:Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis:A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol 72:613-626, 2020
 
8) Seko Y, Yamaguchi K, Umemura A et al:Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia:A single-arm, pilot study. Hepatol Res 50:1328-1336, 2020
PubMed
9) Nakajima A, Eguchi Y, Yoneda M et al:Randomised clinical trial:Pemafibrate, a novel selective peroxisome proliferator-ac-tivated receptor α modulator(SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Phar-macol Ther 54:1263-1277, 2021
 
10) Younossi ZM, Ratziu V, Loomba R et al:Obeticholic acid for the treatment of non-alcoholic steatohepatitis:interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394:2184-2196, 2019
PubMed
11) Loomba R, Noureddin M, Kowdley KV et al:Combination therapies including cilo-fexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepa-tology 73:625-643, 2021
 
12) Dufour JF, Caussy C, Loomba R:Com-bination therapy for non-alcoholic steato-hepatitis:rationale, opportunities and chal-lenges. Gut 69:1877-1884, 2020
 
13) 日本医薬情報センター:JapicCTI-205123. https://www.clinicaltrials.jp/cti-user/trial/Search.jsp
 
14) Boland ML, Laker RC, Mather K et al:Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab 2:413-431, 2020
PubMed
15) Hartman ML, Sanyal AJ, Loomba R et al:Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43:1352-1355, 2020
PubMed
16) Sanyal A, Charles ED, Neuschwander-Tetri BA et al:Pegbelfermin(BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis:a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392:2705-2717, 2018
PubMed
17) Dushay J, Lai M:Is trimming the fat enough? Fibroblast growth factor 21 as an emerging treatment for nonalcoholic fatty liver disease. Hepatology 70:1860-1862, 2019
PubMed
18) Harrison SA, Bashir MR, Guy CD et al:Resmetirom(MGL-3196)for the treat-ment of non-alcoholic steatohepatitis:a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394:2012-2024, 2019
 
19) Ratziu V, Sanyal A, Harrison SA et al:Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis:Final analysis of the phase 2b CENTAUR study. Hepatology 72:892-905, 2020
PubMed
20) Chalasani N, Abdelmalek MF, Garcia-Tsao G et al:Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 158:1334-1345. e5, 2020
 
21) Francque SM, Bedossa P, Ratziu V et al:A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385:1547-1558, 2021
 
P.195 掲載の参考文献
1) de Franchis R;Baveno VI Faculty:Expanding consensus in portal hyperten-sion:Report of the Baveno VI Consensus Workshop:Stratifying risk and individual-izing care for portal hypertension. J Hepa-tol 63:743-752, 2015
 
2) Shi KQ, Fan YC, Pan ZZ et al:Transient elastography:a meta-analysis of diagnos-tic accuracy in evaluation of portal hy-pertension in chronic liver disease. Liver Int 33:62-71, 2013
 
3) Robic MA, Procopet B, Metivier S et al: Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease:a prospective study. J Hepatol 55:1017-1024, 2011
PubMed
4) Berzigotti A:Non-invasive evaluation of portal hypertension using ultrasound elas-tography. J Hepatol 67:399-411, 2017
 
5) Abraldes JG, Bureau C, Stefanescu H et al:Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis:The"Antici-pate"study. Hepatology 64:2173-2184, 2016
 
6) Deng H, Qi X, Zhang T et al:Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases:a meta-analysis. Expert Rev Gastroenterol Hepatol 12:91-98, 2018
PubMed
7) Colecchia A, Colli A, Casazza G et al:Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis:a prospective study. J Hepatol 60:1158-1164, 2014
PubMed
8) Elkrief L, Rautou PE, Ronot M et al:Prospective comparison of spleen and liver stiffness by using shear-wave and tran-sient elastography for detection of portal hypertension in cirrhosis. Radiology 275:589-598, 2015
 
9) Song J, Huang J, Huang H et al:Perfor-mance of spleen stiffness measurement in prediction of clinical significant portal hypertension:A meta-analysis. Clin Res Hepatol Gastroenterol 42:216-226, 2018
 
10)Yamamoto A, Kawada N, Jogo A et al:Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein. Gut 70:1199-1201, 2021
 
11)Villanueva C, Albillos A, Genesca J et al:β blockers to prevent decompensation of cirrhosis in patients with clinically signifi-cant portal hypertension(PREDESCI):a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393:1597-1608, 2019
 
12)Sharma S, Agarwal S, Gunjan D et al:Long-term outcomes with carvedilol ver-sus propranolol in patients with index variceal bleed:6-year follow-up study. J Clin Exp Hepatol 11:343-353, 2021
 
13)Ishikawa T, Sasaki R, Nishimura T et al:Splenic non-infarction volume determines a clinically significant hepatic venous pres-sure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism. J Gastroenterol 56:382-394, 2021
 
14)Korsic S, Stabuc B, Skok P et al:TIPS vs. endoscopic treatment for prevention of recurrent variceal bleeding:a long-term follow-up of 126 patients. Radiol Oncol 55:164-171, 2021
PubMed
15)Bucsics T, Hoffman S, Grunberger J et al:ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver Int 38:1036-1044, 2018
PubMed
16)Drolz A, Schramm C, Seiz O et al:Risk factors associated with bleeding after pro-phylactic endoscopic variceal ligation in cirrhosis. Endoscopy 53:226-234, 2021
 
17)Wang J, Chen S, Naga YM et al:Esopha-geal variceal ligation monotherapy versus combined ligation and sclerotherapy for the treatment of esophageal varices. Can J Gastroenterol Hepatol 2021:8856048, 2021
 
18)Ishikawa T, Sasaki R, Nishimura T et al:A novel therapeutic strategy for esopha-geal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification. PLoS One 14:e0223153, 2019
 
19)Miyamoto S, Yamamoto Y, Takagi T:New method of endoscopic injection sclerosis for esophageal varices using by modified endoscopic hood. Dig Endosc 32:e82-e83, 2020
PubMed
20)Furuichi Y, Abe M, Kasai Y et al:Secure intravariceal sclerotherapy with red dichro-matic imaging decreases the recurrence rate of esophageal varices:A propensity score matching analysis. J Hepatobiliary Pancreat Sci 28:431-442, 2021
 
21)Gwon DI, Ko GY, Yoon HK et al:Gastric varices and hepatic encephalopathy:treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration-a primary report. Radiol-ogy 268:281-287, 2013
 
22)Lee EW, Saab S, Gomes AS et al:Coil-assisted retrograde transvenous oblitera-tion(CARTO)for the treatment of portal hypertensive variceal bleeding:Prelimi-nary results. Clin Transl Gastroenterol 5:e61, 2014
 
23)Shreve L, Lee EW:Role of interventional radiology in complications of portal hyper-tension. J Clin Gastroenterol 53:342-349, 2019